Louisiana State University

LSU Digital Commons
LSU Doctoral Dissertations

Graduate School

2004

A study of the anti-inflammatory, anti-microbial and
immunomodulatory properties of thalidomide in leprosy
Azeb Tadesse Argaw
Louisiana State University and Agricultural and Mechanical College

Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations
Part of the Veterinary Pathology and Pathobiology Commons

Recommended Citation
Tadesse Argaw, Azeb, "A study of the anti-inflammatory, anti-microbial and immunomodulatory properties
of thalidomide in leprosy" (2004). LSU Doctoral Dissertations. 2137.
https://digitalcommons.lsu.edu/gradschool_dissertations/2137

This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It
has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU
Digital Commons. For more information, please contactgradetd@lsu.edu.

A STUDY OF THE ANTI-INFLAMMATORY, ANTI-MICROBIAL
AND IMMUNOMODULATORY
PROPERTIES OF THALIDOMIDE IN LEPROSY

A Dissertation
Submitted to the Graduate Faculty of the
Louisiana State University and
Agricultural and Mechanical College
in partial fulfillment of the
requirements for the degree of
Doctor of Philosophy
in
The Interdepartmental Program in
Veterinary Medical Sciences through the
Department of Pathobiological Sciences

By
Azeb Tadesse Argaw
B.S., Addis Ababa University, 1991
M.Ph., University of Bergen, 1998
August 2004

ACKNOWLEDGEMENTS
First and foremost I would like to thank Almighty God for giving me the strength to carry on
throughout my study period. “Who am I, O Lord GOD, and what is my house, that thou hast
brought me thus far” 2 Samuel 7:18.
I am highly indebted to my family, especially my mother Asrat Negash who has sacrificed all
her life for her children. She will attend my graduation representing not only her but also my
father, who dreamed to see this special day. I would also like to express my gratitude for my
sisters and brother for giving me supports and encouragements during difficult moments.
When I came to Baton Rouge in May 2001, I was disturbed by the change in weather and life
style. I am greatly indebted to Mrs G. Shannon for helping me settle in a smooth way.
This work was made possible with the assistance of different people who took their time to
teach me and help me. I would like to express my gratitude for Dr E.J. Shannon my major
professor, for giving me a chance to fulfill my dream and for providing all the help I needed. My
thanks also goes to my graduate advisory committee, Dr J.L. Krahenbuhl for helping me with the
murine experiments and giving me helpful advices, Dr J.B. Malone for giving me the chance to
learn GIS and Dr J.E. Miller for his patience in reading my manuscripts and giving me detailed
comments.
A major part of the lab work was done at the Armauer Hansen Research Institute (AHRI) in
Ethiopia. I would like to thank all AHRI staff that contributed to this work; especially Dr H.
Engers for his constructive comments and encouragements; Dr A. Aseffa for his support and
ii

corrections of manuscripts; Dr E. Bizuneh and Dr T. Engeda for recruiting patients, Dr W.
Mulugeta who joined the work at later part and surprised me with his dedication and hard work;
M. Abebe who has done most of the PCR works and helped with the tedious task of RNA
extraction by staying even overtime when needed; Dr A. Demissie for helping with the RT-PCR
work and sharing reagents ; R. Abebe and L. Wassie for helping with the RNA extraction; my
friend A.Tadesse W/G for being there for me and helping me with lab works; W. Alemu for her
friendship and Sr G. Amare and S.G/Tsadik for sample collection.
Since I first joined in the lab of the National Hansens Disease Program (NHDP), I was
amazed by people’s friendliness. I would like to express my appreciation for all the staff
especially C. Lewis, K. Andrews and V. Tulagan making me feel at ease in this new
environment, B. Randawal for her positive energy and for helping me with the Buddemeyer
assays; N. Ray for helping me with cell works; JP Pasqua for his kindness and work in M. leprae
isolation and G. McKormick for helping me with photography.
In the GIS lab I would like to thank K. Gruzynski for her kindness and for helping me with
GIS and for helping with the graphs and picture for my dissertation; K. McNally for helping me
with ArcView and Ms. S. Wiles for her smile and hospitality.
Last but not least I would like to thank all my friends who encouraged me and helped me
throughout my study periods especially J.Lott Jr. and A. Israelyan.

iii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS....................................................................................................... ii
ABSTRACT .............................................................................................................................. vii
CHAPTER 1 INTRODUCTION.............................................................................................. 1
1.1 History of Thalidomide ................................................................................................... 1
1.2 Chemical Properties ........................................................................................................ 2
1.3 Pharmacokinetics ............................................................................................................ 3
1.4 Therapeutic Uses ............................................................................................................. 4
1.5 Adverse Effects ................................................................................................................ 5
1.6 Thalidomide and Erythema Nodosum Leprosum (ENL) ............................................ 6
1.6.1 Historical Perspectives ........................................................................................... 6
1.6.2 ENL ........................................................................................................................ 6
1.6.3 Histopathology........................................................................................................ 7
1.6.4 Immunology of Reactions in Leprosy .................................................................... 8
1.6.5 Possible Mechanism of Action of Thalidomide in The Treatment of ENL ......... 10
1.7 Thalidomide in Cancer ................................................................................................. 19
1.8 Aim.................................................................................................................................. 21
CHAPTER 2 THE EFFECT OF THALIDOMIDE ON THE IMMUNE RESPONSE
OF CELLS FROM LEPROSY PATIENTS .......................................................................... 23
2.1 Introduction ................................................................................................................... 23
2.2 Material and Methods................................................................................................... 24
2.2.1 Study Subjects ...................................................................................................... 24
2.2.2 Thalidomide.......................................................................................................... 25
2.2.3 Antigens Prepared from Mycobacteria................................................................. 25
2.2.4 Cell Cultures ......................................................................................................... 26
2.2.5 Assay for Lymphocyte Blast Transformation ...................................................... 27
2.2.6 Determination of TNF-α ...................................................................................... 28
2.3 Results............................................................................................................................. 28
2.3.1 Proliferative Responses in the Absence of Thalidomide...................................... 28
2.3.2 Effect of Thalidomide on Proliferative Responses............................................... 29
2.3.3 Effect of Thalidomide on Synthesis of TNF-α..................................................... 29
2.4 Discussion ....................................................................................................................... 32
CHAPTER 3 THE EFFECT OF THALIDOMIDE ON THE EXPRESSION OF TNF-α
α
MRNA AND THE SYNTHESIS OF TNF-α
α IN CELLS FROM LEPROSY PATIENTS
WITH REVERSAL REACTION ........................................................................................... 36
3.1 Introduction .................................................................................................................. 36
3.2 Material and Methods................................................................................................... 37
iv

3.2.1 Study Subjects ...................................................................................................... 37
3.2.2 Thalidomide.......................................................................................................... 38
3.2.3 Antigens................................................................................................................ 39
3.2.4 Cell Cultures ......................................................................................................... 39
3.2.5 Assay for Lymphocyte Blast Transformation ...................................................... 40
3.2.6 Determination of TNF-α ...................................................................................... 40
3.2.7 Analysis of Data ................................................................................................... 43
3.3 Results............................................................................................................................. 43
3.3.1 Lymphocyte Proliferation..................................................................................... 43
3.3.2 Effect of Thalidomide on Lymphocyte Proliferation ........................................... 44
3.3.3 Effect of Thalidomide on the Synthesis of TNF-α............................................... 44
3.3.4 Effect of Thalidomide on TNF-α MRNA Level .................................................. 46
3.3.5 Thalidomide-Induced Enhancement of TNF-α and TNF-α MRNA.................... 48
3.4 Discussion ....................................................................................................................... 50
CHAPTER 4 THE EFFECT OF THALIDOMIDE ON THE VIABILITY OF
INTRACELLULAR M. LEPRAE IN ACTIVATED MACROPHAGES .......................... 55
4.1 Introduction .................................................................................................................. 55
4.2 Materials and Methods ................................................................................................. 56
4.2.1 Source of M. Leprae ............................................................................................. 56
4.2.2 Mouse Peritoneal Macrophages............................................................................ 56
4.2.3 Treatment Condition............................................................................................. 57
4.2.4 Activation of Macrophages- Infection- Treatment with Thalidomide ................. 57
4.2.5 Assessment of M. Leprae Viability: Radiorespirometric Assay .......................... 58
4.2.6 Assessment of TNF-α in Activated Macrophages ............................................... 59
4.2.7 Nitrite Assay ......................................................................................................... 59
4.3 Results............................................................................................................................. 60
4.3.1 Assessment of Metabolic Activity of Intracellular M. Leprae ............................. 60
4.3.2 Effect of Thalidomide on Viability of M. Leprae ................................................ 61
4.3.3 TNF-α and Nitrite Levels in Activated Macrophages.......................................... 62
4.3.4 Morphological Appearance of Peritoneal Macrophages ...................................... 62
4.4 Discussion ....................................................................................................................... 64
CHAPTER 5 THE EFFECT OF THALIDOMIDE ON THE INTEGRITY OF
PLASMA CELL MEMBRANES............................................................................................ 67
5.1 Introduction ........................................................................................................................ 67
5.2 Materials and Methods ...................................................................................................... 68
5.2.1 Preparation of Thalidomide................................................................................... 68
5.2.2 In Vitro Thalidomide Treatment ........................................................................... 68
5.2.3 Ex Vivo Thalidomide Treatment .......................................................................... 69
5.2.4 Osmotic Fragility................................................................................................... 69
5.2.5 THP-1 Cell Culture ............................................................................................... 70
v

5.2.6 THP-1 Membrane Fragility Experiments.............................................................. 71
5.2.7 Isolation of Neutrophils and Fragility Experiments.............................................. 71
5.2.8 LDH Assay............................................................................................................ 72
5.3 Results ................................................................................................................................. 72
5.3.1 Thalidomide Stabilized the Erythrocyte Membrane ............................................. 72
5.3.2 Effect of Thalidomide on LDH Release by Neutrophils....................................... 73
5.3.3 Effect of Thalidomide on LDH Release by THP-1 Cells ..................................... 73
5.3.4 Influence of Ingested Thalidomide on Osmotic Fragility of RBC........................ 74
5.4 Discussion............................................................................................................................ 76
CHAPTER 6 CONCLUSION ................................................................................................. 79
REFERENCES ......................................................................................................................... 82
APPENDIX RELEVANT EXTRA MATERIAL .................................................................. 94
VITA........................................................................................................................................ 111

vi

ABSTRACT
During the course of their disease, leprosy patients may experience two types of
inflammatory reactions- erythema nodosum leprosum (ENL) or reversal reaction (RR).
Thalidomide is effective treatment for ENL, but not for RR. Using concentrations of thalidomide
similar to that achieved in the treatment of ENL, we investigated thalidomide’s effect on
reactions, viability of M. leprae, and integrity of plasma membranes.
Cells from patients with and without RR were stimulated with M. leprae (AFB), a cytosol
fraction of M. leprae (MLSA) or DHAR (DHAR) antigen, and the effect of thalidomide on
lymphocyte proliferation, expression of TNF-α mRNA and synthesis of TNF-α was
investigated. Thalidomide enhanced MLSA and DHAR induced proliferation of cells from
patients with RR.

The expression of TNF-α mRNA was variable, but thalidomide generally

suppressed the synthesis of TNF-α. In a sub-set of RR patients, thalidomide enhanced AFBinduced cell proliferation, and the expression of TNF-α mRNA and TNF-α.
ENL has been described as a consequence of M. leprae antigens released from
macrophages binding antibody and inducing inflammation. Thalidomide did not affect the
viability of M. leprae residing in IFN-γ/LPS activated mouse macrophages, nor did it suppress
TNF-α or nitrite.
Drugs may be anti-inflammatory by stabilizing cell membranes. Thalidomide failed to
protect the plasma membrane of neutrophils and THP-1 cells from osmotic lysis. Thalidomide
stabilized the membrane of erythrocytes from plasma free blood, but not from whole blood. In
vii

vivo, the stability of erythrocytes membranes from subjects after ingestion of thalidomide was
not affected.
In conclusion, thalidomide did not alter the viability of M. leprae, nor the integrity of the
plasma membrane of inflammatory cells. It could enhance or suppress M. leprae antigeninduced synthesis of TNF-α. Interestingly, in 15 of 75 RR patients cells stimulated with AFB,
thalidomide acted as a co-stimulant enhancing cell proliferation, synthesis of mRNA for TNF-α
and TNF-α. Thalidomide’s enhancing effect on TNF-α in RR appears to be dependent on the
stimulant and IL-2 signaling. As the inflammation in RR is associated with the emergence of
antigen-reactive T-cells and TNF-α, we speculate that the use of thalidomide in the treatment of
RR may exacerbate the reaction.
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CHAPTER 1 INTRODUCTION
1.1 History of Thalidomide
Chemie Grünenthal, a German pharmaceutical company, synthesized thalidomide in
1954. It was initially produced as a potential anti-histaminic drug but later discovered to possess
marked sedative properties. Thalidomide’s lack of toxicity in rodents at doses as high as 10g/kg
facilitated its availability as an over-the-counter drug and by 1960, thalidomide was widely
marketed in more than 20 countries. It quickly became a drug for the treatment of nausea
associated with morning sickness during pregnancy. In 1961, suspicion regarding thalidomide’s
link with birth defects characterized by severe malformations started to appear. After more than
10,000 documented devastating cases of birth defects, thalidomide was withdrawn from the
market in 1961 (Zwingerberger, K. and Wnendt, S., 1996).
In 1965, thalidomide made a major comeback after the accidental discovery of its dramatic
effect in the treatment of an immunological reaction in leprosy known as erythema nodosum
leprosum (ENL) (reviewed in Sheskin, J., 1980). Until 1998, thalidomide in the United States
(US) was available only as an investigative new drug from the National Hansen Disease Program
in Carville, Louisiana. In July 1998, the Food and Drug Administration (FDA) approved
thalidomide for the treatment of ENL (FDA, 1998). Thalidomide is currently marketed in the US
under the name Thalomid® (Thalidomide) by Celgene Company (Warren, New Jersey). In
March 1999, the FDA in collaboration with Celgene implemented a distribution and training
program known as System for Thalidomide Education and Prescribing Safety (S.T.E.P.S). In
1

order to guard against fetal exposure to thalidomide, this program requires physicians and
pharmacists to register with the FDA before they can dispense thalidomide and all patients to
complete an informed consent process and must agree to participate in a mandatory confidential
surveillance registry (Zeldis, J.B. et al, 1999). In November 2001, Celgene expanded the
availability of thalidomide worldwide by signing an agreement with Pharmion (Boulder,
Colorado) a pharmaceutical company with European and Asian branches. In 2003, Thalomid®
was granted approval by the Australian and New Zealand governments for the treatment of ENL
as well as for the treatment of relapsed and refractory multiple myeloma (Celgene, website).
1.2 Chemical Properties
Thalidomide,

α-phthalimidoglutarimide

or

1,3-dioxo-2-(2’,6’–dioxopiperidin-3’-yl)

isoindoline is a white crystalline powder and has the following structural formula.

2

It has two ring systems, the phthalimide moiety on the left, and the glutaramide moiety
on the right. Due to the asymmetry of the carbon atom (c*), on the glutaramide ring, thalidomide
exists in optically active L and R isomers. In vivo, thalidomide inter-converts between isomeric
forms to give an optically inactive racemic mixture. This inversion is very fast at 37 0C and is
catalyzed by human serum albumin (Eriksson, T. et al, 1998). Thalidomide is insoluble in ether
and benzene, sparingly soluble in water and ethanol and readily soluble in dimethyl sulfoxide
(DMSO) and chloroform (The Merck Index, 1968).
At a pH of 6.0 and above, the 4-amide bonds of thalidomide (indicated by arrows)
become susceptible to OH- ions and undergo hydrolytic cleavage, yielding 4 major compounds,
which undergo further breakdown to yield 8 compounds (Czejka, M.J. et al, 1987).
1.3 Pharmacokinetics
Thalidomide is absorbed slowly from the gastro-intestinal tract and is distributed
throughout body fluids and tissues (Perri III, A.J. and Hsu, S., 2003). The pharmacokinetics of
thalidomide has been studied in healthy as well as diseased individuals. With the exception of
patients with Acquired Immuno-Deficiency Syndrome (AIDS), who may have gastro-intestinal
absorption problems, thalidomide at a dose of 200 - 400 mg per os, achieves a peak plasma
concentration of 1.15 – 3.44 mg/ml in 3 – 7 hours (hrs). The absorption half-life (T1/2) is 1.5 –
1.7 hrs; whereas, the elimination T1/2 is between 6.5 and 8.7 hrs (Eriksson, T. et al, 2001).
Thalidomide is mainly degraded by spontaneous hydrolysis in the blood and tissues. A minute
quantity of the drug is also metabolized by the hepatic cytochrome P450 system (Mujagic, H. et
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al, 2002). Thalidomide is not excreted renally as indicated by the presence of less than 0.7% of
intact drug in urine (Eriksson, T. et al, 1998).
1.4 Therapeutic Uses
Due to its anti-inflammatory, immuno-modulatory and anti-angiogenic properties,
thalidomide is an effective treatment for a variety of clinical conditions. Currently, the only FDA
approved indication for thalidomide is in the treatment of ENL (FDA, 1998).

However,

thalidomide has given promising therapeutic effects in various dermatological disorders like
Behcet’s disease (Hamuryudan, V. et al, 1998), chronic lupus erythematosus (Stevens, R.J. et al,
1997) actinic prurigo and prurigo nodularis (Perri III, A.J. and Hsu, S., 2003). It is also shown to
be effective in Crohn’s disease (Odeka, E.B. and Miller, V., 1997). Thalidomide has also been
used for the treatment of graft-versus-host-disease (GVHD) both in a murine model and
subsequently in a phase II trial (Voglesgang, G.B. et al, 1989; Voglesgang, G.B. et al, 1992;
Cole, C.H. et al, 1994). But attempts to use thalidomide as a prophylactic agent in the prevention
of GVHD resulted in a paradoxical outcome with thalidomide treated patients having a higher
incidence in GVHD and a lower overall survival (Chao, N.J. et al, 1996). In complications
related to HIV, thalidomide has been shown to treat wasting syndrome (Kaplan, G. et al, 2000),
oropharyngeal, oesophageal and rectal apthous ulceration (Youle, M. et al, 1989; Jacobson, J. et
al 1997), Mycobacterium Avium complex (MAC)–related infections (Bouza, E. et al, 1992) and
microsporidial diarrhea (Sharpstone, D. et al, 1995).
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1.5 Adverse Effects
The most severe side effect of thalidomide is teratogenicity. Thalidomide can easily cross
the placenta and affect normal fetus formation. A single dose of 50 mg tablet in the first trimester
of pregnancy has been reported to cause birth defects. The principal defect observed in a fetus is
phocomelia where the hands and feet are attached to abbreviated arms and legs due to a poorly
developed limb. In severe cases complete absence of limbs have been recorded. Additional
abnormalities may include malformations of ears, bones, face, eyes, gastro-intestinal and
genitourinary tracts. About 40% of exposed fetuses die at or shortly after birth (Perri III, A.J. and
Hsu, S., 2003). The S.T.E.P.S. program for fetus protection ensures that thalidomide will not be
given to pregnant women (Zeldis, J.B. et al, 1999).
Another potential adverse effect with prolonged use of thalidomide is peripheral
neuropathy with risk of irreversible damage. This includes symmetrical, painful paresthesis of
hand and feet often accompanied by numbness of lower limbs. Hypersensitivity reactions
manifested by erythematous macular skin eruptions which if untreated could lead to fever,
tachychardia and hypotension have also been reported. Somnolence and dizziness due to sedative
properties of thalidomide have also been noted (Tseng, S. et al, 1996). Constipation can occur in
some patients, which can lead to noncompliance if severe. Neutropenia is a rare side effect and is
more common in HIV patients. In HIV-infected individuals, an increase in viral (median increase
0.42 log10 per milliliter) load has been reported after administration of thalidomide for the
treatment of oral aphthous ulcers (Jacobson, J. et al, 1997).
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1.6 Thalidomide and Erythema Nodosum Leprosum (ENL)
1.6.1

Historical Perspectives
The ability of thalidomide to effectively treat ENL was accidentally discovered in 1965,

shortly after its ban from the world market. Professor Jacob Sheskin, an Israeli Dermatologist
and Leprologist, was confronted with a patient suffering with ENL. In order to appease the
patient’s difficulty to sleep due to severe pain, Prof Sheskin gave him thalidomide as a sedative.
Within 48 hours, he observed a significant improvement in the clinical manifestations of ENL.
Prof. Sheskin reported his findings as an empirical study involving 6 ENL patients (Sheskin, J.,
1980). Thereafter, various well-controlled clinical trials have shown the efficacy of thalidomide
in the treatment of ENL. All of these studies, including a multi-centered worldwide survey
organized by the World Health Organization (WHO) showed an efficacy of thalidomide in ENL
as high as 90-99 % (Sheskin, J. 1980). The recommended dose of thalidomide in the treatment of
ENL is initially 100 mg 3 to 4 times a day and tapered to 100 to 50 mg/day for maintenance dose
(Hastings, R.C., 1985). Thalidomide alleviates symptoms of ENL 1-2 weeks after initiation of
therapy. Systemic symptoms like fever, malaise, arthritic and neuritic pains dissipate within 2448 hours after ingesting thalidomide. Disappearance of lesions takes relatively more time
(Sampaio, E.P. et al, 1993)
1.6.2

ENL
ENL is an immunological reaction that occurs in 20 to 25 % of borderline leprosy and

lepromatous leprosy patients. ENL occurs frequently after onset of treatment, but is also seen in
untreated as well as treated patients (Petit, J.H.S. et al, 1967). ENL may be precipitated by
6

factors like pregnancy and parturition, protective immunization, stress, intercurrent infection and
surgical operation (Jopling, W. H., 1988)
The major symptom of ENL is the appearance of crops of painful erythematous nodular
lesions, which persist for days and then subside. These skin lesions, which are distinct from
existing leprosy lesions, are round or oval and mainly appear on the face, trunk and extremities
(Job, C.K. et al, 1964). Peripheral neuropathy especially polyneuritis with risks of disability, is
another major complication of ENL. Patients also have severe symptoms of fever and general
malaise. Other complications include arthralgia, polyarthritis, irritis and orchitis (Job, C.K. et al,
1964; Hastings, R.C., 1985).
1.6.3

Histopathology
ENL lesions are characterized with dense cellular infiltrates extending from lower dermis

into sub-cutaneous fat (Job, C.K., et al 1964). At an early stage, lesions are characterized by a
massive infiltration with polymorphonuclear neutrophils (PMN). As the inflammation subsides,
the dominant cells in the lesion are lymphocytes and plasma cells. A slight increase in the
number of histiocytes was also observed in chronic stages of ENL. The early stages of reaction
also exhibit vasculitis due to swelling and edema of endothelium and to infiltration of blood
vessel walls by PMN and eosinophils. The center of ENL lesions contain disintegrated
histiocytes and fragmented and granulated acid-fast bacilli (Mabalay, M.C. et al, 1965; Ridley,
M.J. and Ridley, D.S., 1983).
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1.6.4

Immunology of Reactions in Leprosy
During the course of their disease, leprosy patients exhibit two types of immunological

reactions. Dr W.H Jopling classified these reactions as Type I or reversal reaction (RR) and Type
II reaction or ENL (Jopling, W.H., 1971). This classification is different from that of Gell and
Coombs, who categorized reactions into four types. Type I hypersensitivity reactions are caused
by IgE and allergens in complexes on mast cells. This results in mast cells degranulation and the
release of inflammatory mediators like histamine. Type II hypersensitivity reactions are caused
by covalent interactions of small molecules, like degradation products of penicillin, with cell
surface components producing modified structures recognized as foreign by IgG antibodies.
Type III hypersensitivity reactions are initiated by soluble immune complexes that get deposited
on walls of blood vessels. These initiate complement fixation with marked neutrophilic
infiltration resulting in tissue injury. Type IV hypersensitivity reactions are cell-mediated and
occur due to an emergence of effector T-cells that react with antigens resulting in responses that
may include macrophage activation, cytokine production and cytotoxicity (Williams, E.P., 2003).
In leprosy, reversal reaction (RR) mainly occurs in borderline leprosy patients and is
caused by an increase in T-cell mediated immunity to M. leprae antigens expressed on dermal
macrophages and Schwann cells. RR belongs to Type IV hypersensitivity group in the Gell and
Coomb classification (Hastings, R.C., 1985). Clinical manifestations include a rapid change in
the appearance of existing leprosy skin lesions, which become erythematous, more prominent,
shiny and warm to touch. These lesions might sometimes break and ulcerate. A rapid swelling
and inflammation of nerves with risks of motor disturbance is common. In RR, systemic
8

symptoms are very rare (Jopling, W.H., 1983). A transient influx of lymphocytes into lesions
occurs at early stages. Edema around granulomatous lesions is very common. The cellular
contents of granuloma changes progressively towards a more epitheloid form resulting in
subsequent destruction of the bacilli within the granuloma (Ridley, D.S., 1969). RR is
accompanied by an increase in the response and frequency of M. leprae-reactive T-cells in
peripheral blood (Bjune, G. et al, 1976). Studies of skin lesions have demonstrated the
infiltrating T-cells to be of CD4+ phenotype. These T-cells show a ten-fold increase in IFN-γ
production, a cytokine that causes activation of macrophages with subsequent elimination of
bacilli and the induction of delayed-Type Hypersensitivity reaction (DTH) (Cooper, C.L. et al,
1989).
ENL is thought to be caused by antibody as well as cell-mediated immune processes.
ENL was initially proposed to be a Type III hypersensitivity reaction due to the similarity of
some of its symptoms like albuminuria and erythema to those encountered in serum sickness or
in the experimental Arthus reactions (Ulrich, M. et al, 1971). The formation of immune
complexes may be expected in lepromatous leprosy due to the concomitant presence of large
amount of mycobacteria and their corresponding antibody (Shannon, E.J. et al, 1981). The
presence of fixed complement and immunoglobulin deposits in ENL lesions has been
demonstrated (Wemambu, S.N. et al, 1969). However demonstration of immune complexes and
complement products in circulation has been an elusive task in ENL. Complement activation in
ENL has also been shown by an increase in the complement split product C3d in serum of
patients with active ENL. Determination of immune complexes in plasma of these same patients
9

by C1q-binding activity revealed a poor correlation between these complexes and the C3d level.
This strongly indicates that immune complexes in ENL are extra-vascular (Bjorvatn, B. et al,
1976).
An additional and unique characteristic in the leprosy patients experiencing ENL is a
transient improvement in T-cell functions indicating the involvement of a cell-mediated
component as well. During the acute stage of ENL an emergence of reactive T-cells was
demonstrated as shown by an enhancement in mitogen as well as M. leprae-antigen-induced
lymphocyte proliferation. (Laal, S. et al, 1985). Immunohispathologic studies using in situ
immunoperoxidase staining have demonstrated that ENL lesions have an increase in the
percentage of cells with receptors for IL-2 and an increase in CD4+ T-cells (Modlin, R.L. et al,
1986; Sampaio, E.P. et al, 1993). In ENL lesions enhanced expression of intercellular adhesion
molecules (ICAM-1), leukocyte function antigen 1 (LFA-1) (Sullivan, L. et al, 1991) and
expression of major histocompatibility complex class II (MHC II) molecules on immune cells
and keratynocytes have also been described (Thangaraj, H. et al, 1988, Sampaio, E.P. et al,
1993).
1.6.5

Possible Mechanisms of Action of Thalidomide in the Treatment of ENL
Several studies have attempted to elucidate the mechanism of action of thalidomide in

arresting ENL. Two main properties, anti-inflammatory and immunomodulatory represent the
leading hypothesis regarding thalidomide’s mechanisms.
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1.6.5.1 Effect on Phagocytic cells
The influx of polymorphonuclear neutrophils (PMN) in early lesions and macrophages in
ENL has prompted investigators to study the effect of thalidomide on chemotaxis, phagocytosis
and effector mechanisms of phagocytic cells.
1.6.5.1.1 Expression of Cell Adhesion Molecules and Chemotaxis
In order to reach sites of inflammation, phagocytic cells in the blood must adhere and
pass between the endothelial cells lining the walls of blood vessels. This migration process
occurs in a step-wise fashion with the leukocyte rolling, tethering, adhering and then
extravasation. These steps are mediated by interactions of cell surface molecules expressed on
leukocytes and on vascular endothelial cells. Leukocyte rolling and tethering are mediated by
selectins expressed on circulating leukocytes (L selectin) and on vascular endothelial cells (E and
P selectins). Mucins, which are heavily glycocylated proteins, also interact with selectin in the
initial phase of leukocyte adherence. A firm adhesion requires the interaction of integrins, such
as LFA-1, Mac-1, and very late antigen-4 (VLA-4) expressed on leukocytes surfaces. Members
of the immunoglobulin superfamily intercellular adhesion molecules (ICAMS) and vascular cell
adhesion molecules (VCAM) pertain to distinct adhesion pathways. The ICAM-LFA-1 or Mac-1
pathway is mediated by constitutively expressed ligands whereas the VCAM-1/VLA-4 pathway
bind to cytokine stimulated endothelial cells. (Williams, E.P., 2003).
Thalidomide’s ability to modulate the adhesion cascade was investigated as a possible
mechanism of action for this drug. Thalidomide is shown to enhance the shedding of L-selectin
from PMN and to down regulate the expression of the inducible receptor of VCAM-1, which
11

might to some extent explain its anti-inflammatory mechanism. But contrary to expectations,
thalidomide enhanced the TNF-α-mediated expression of ICAM-1 indicating a rather complex
mechanism of interaction (Geitz, H. et al, 1996). Thalidomide is also shown to enhance the TNFα-induced transmigration of PMN across a layer of human umbilical vein endothelial cells
(HUVEC). It also synergized with TNF-α in the suppression of undirected as well as IL-8 and Nformyl-methionyl-leucyl-phenylalanine (fMLP)-mediated PMN chemotaxis (Dunzendorfer, S. et
al, 1997).
1.6.5.1.2 Phagocytosis
The effect of thalidomide on phagocytosis is variable. In an experiment involving the
phagocytosis of small latex beads thalidomide exhibited a bimodal activity with enhancement of
the phagocytosis by monocytes at a 1.0 µg/ml and suppression at 10 µg/ml; whereas for PMN, it
only suppressed the phagocytosis at 10 µg/ml and failed to affect it at the lower dose (Barnhill,
R.L. et al, 1984). Thalidomide failed to affect the phagocytosis of larger zymosan particles by
PMN (Hastings, R.C. et al, 1978).
1.6.5.1.3 Oxidative Effector Mechanism
Thalidomide failed to affect the respiratory burst of PMN as shown by
chemiluminescence experiments (Dunzendorfer, S. et al, 1997) as well as Nitro Blue
Tetrazolium reduction assay

(NBT) (Golhman-Yahr, M. et al, 1978); whereas,

chemiluminescence of monocytes was significantly depressed by thalidomide (Barnhill, R.L. et
al, 1984).
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1.6.5.1.4 Modulation of Cytokine Production by Thalidomide


TNF-α

The presence of monocytes and lymphocytes in ENL lesions affords an opportunity for
local production of inflammatory cytokines by these cells. TNF-α is one of the major cytokines
produced by monocyte/macrophages. An enhanced level of TNF-α was detected in skin biopsies
as well as in serum from ENL patients (Parida, S.K. et al, 1992; Moraes, M.O. et al, 1999).
Thalidomide’s mechanism in treating ENL is thought to be associated with its ability to partially
inhibit the production of TNF-α. This reduction in TNF-α was first demonstrated in vitro in
endotoxin or M. leprae-stimulated human monocytes (Sampaio, E.P. et al, 1991) and then in vivo
in thalidomide-treated ENL patients (Sampaio, E.P. et al, 1993). So far, three mechanisms of
TNF-α suppression by thalidomide have been described: (1) thalidomide was shown to reduce
the half-life of TNF-α messenger RNA (mRNA) from 30 to 17 minutes (Moreira, A.L., et al
1993); (2) thalidomide is also shown to block NF-kB, a transcription factor involved in the
regulation of several genes including TNF-α gene (Keifer, J.A. et al, 2001); (3) thalidomide is
also shown to bind to α1-acid glycoprotein, a pro-inflammatory protein that belong to the acute
phase proteins family (Turk, B.E. et al, 1996).
The suppression of TNF-α by thalidomide in conditions other than ENL was observed in
tuberculosis (TB) patients with or without a co-infection with HIV (Tramontana, J.M. et al,
1985).
The inhibitory effect of thalidomide on TNF-α became controversial when studies
indicating an enhanced production of TNF-α by thalidomide, started to appear. In 1996, Shannon
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et al showed thalidomide to enhance TNF-α production by LPS-stimulated human monocytes as
well as in the LPS-stimulated THP-1-monocyte-like cell line (Shannon, E.J. and Sandoval, F.,
1996). This work supported subsequent findings of thalidomide-induced enhancement of TNF-α
in the serum of apthous ulcers in HIV patients (Jacobson, J. et al, 1997) and in toxic epidermal
necrolysis (Wolkenstein, P. et al, 1998). A recent study by Marriott et al has explained the
varying effect of thalidomide on TNF-α as being conditional on the stimulant and the cell
stimulated. In T-cell-independent systems like LPS-stimulated monocytes, thalidomide
suppresses TNF-α; whereas, in a T-cell-dependent system such as PBMC stimulated by crosslinking of T-cell receptor (TCR), thalidomide can enhance the production of TNF-α. This
enhancement is seen at late stages of incubation (48-72 hours) and is thought to be dependent on
IL-2 signaling (Marriott, J.B. et al, 2002).


Cytokines Other Than TNF-α

The effect of thalidomide on the monocyte production of the pro-inflammatory cytokines
IL-1 and IL-6 is not very clear. Thalidomide (0.1-10 µg/ml) was shown to have no effect on the
production of IL-1β, IL-6 or granulocyte macrophage colony stimulating factor (GM-CSF) by
monocytes from healthy humans stimulated with LPS (Sampaio, E.P. et al, 1991). On the other
hand, the release of IL-1 by LPS-stimulated PBMC from TB patients was suppressed in
thalidomide-treated patients. In this same study the in vivo treatment of TB patients with
thalidomide failed to affect the plasma IL-1 level (Tramontana, J.M. et al, 1985).
Thalidomide affects the production of IL-12 in a selective manner similar to its effect on
TNF-α. In LPS stimulated monocytes, it suppressed the production of IL-12 (Moller, D.R. et al,
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1997) whereas in T-cells stimulated via the TCR, it enhanced the production of IL-12 (Corral,
L.G. et al, 1999).
1.6.5.2 Modulation of Lymphocyte Activity by Thalidomide
1.6.5.2.1 Lymphocyte Proliferation
The effect of thalidomide on primary T-cell responses has been difficult to evaluate using
lymphocyte proliferation assay. Treatment of antigen or mitogen stimulated peripheral blood
mononuclear cells (PBMC) from healthy as well as HIV and/or TB patients has given
inconsistent results. Thalidomide given in vivo as well as in vitro in PBMC cultures from
healthy individuals failed to affect lymphocyte proliferation in response to Concanavalin A
(ConA) or purified protein derivatives (PPD) (Santos-Mendoza, T. et al, 1996). Günzler et al
obtained a similar result in PBMC from healthy individuals stimulated with ConA and treated in
vitro with 5 or 40 µMol/l (1.29-10.3 µg/ml) of thalidomide (Günzler, V. et al, 1986). In a study
of tuberculosis (TB) patients with or without HIV co-infection, thalidomide treatment in vivo
failed to significantly affect the ability of PBMC to proliferate in response to mycobacterial
antigens (Tramontana, J.M. et al, 1985). Thalidomide at 3-30 ug/ml, failed to affect the ability of
PBMC from a healthy individual to incorporate 3H-thymidine in response to phytohemagglutinin
(PHA) and phorbol myristate acetate (PMA) (Fernandez, L.P. et al, 1995).
Some studies have demonstrated thalidomide’s ability to suppress or stimulate the
response of PBMC to various antigens and mitogens. Thalidomide suppressed the mitogenic and
allogeneic stimulations of lymphocytes from healthy donors (Keenan, R.J. et al, 1991). In vitro
treatment of thalidomide resulted in an enhanced proliferative response of PBMC from healthy
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volunteers stimulated by cross-linking of the T-cell receptor (TCR) by immobilized monoclonal
mouse anti-human CD3 antibody (Corral, L.G. et al, 1999). Similarly, in a study of whole
PBMC as well as purified CD4+ and CD8+ T-cells from HIV-infected individuals, treatment with
thalidomide at 1 and 10 µg/ml enhanced proliferative responses of these cells to anti-CD3
antibodies (Haslett, P.A.J. et al, 1998). The varying effect of thalidomide on lymphocyte
proliferation assay was recently explained to be dependent on the types of dominant cell
population and the signaling pathway involved. In T-dependent systems, thalidomide act as a
secondary co-stimulator required for optimal T-cell activation resulting in enhanced
proliferation. This was demonstrated in PBMC stimulated with the T-cell receptor cross-linker
anti-CD3 antibody, where thalidomide enhanced the proliferation of PBMC in a concentration
dependent fashion (Marriott, J.B. et al, 2002; Corral, L.G. et al, 1999).
1.6.5.2.2 T-cell Cytokine Production
Thalidomide is shown to enhance the production of TNF-α in T-cell dependent systems.
CC-4047 is an analogue of thalidomide classified as an ImiDs (immunomodulatory drugs). CC4047 is functionally similar to but more potent than thalidomide. A study involving CC-4047 has
shown that the sources of elevated TNF-α are activated lymphocytes. This thalidomide-induced
production of TNF-α occurs as a late event and is dependent on IL-2–mediated signalling.
Abrogation of the IL-2 signal by anti-IL-2 antibody disrupted the enhancement of TNF-α by
CC-4047 (Marriot, J.B. et al, 2002).
Several works have shown that thalidomide enhances the production of IL-2 by healthy
as well as HIV-infected PBMC stimulated with mitogen and antigens (Shannon, E.J. and
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Sandoval, F., 1995; Santos-Mendoza, T. et al, 1996; Marriott, J.B. et al, 2002; Haslett, P.A.J. et
al, 1998). One particular group, which studied the expression of IL-2 by Jurkat cells, in response
to PHA/PMA-induced stimulation, failed to demonstrate an effect of thalidomide on IL-2
(Fernandez, L.P. et al, 1995).
Thalidomide also enhanced the production of IFN-γ by mycobacterial antigen stimulated
PBMC from thalidomide-treated TB patients (Tramontana, J.M. et al, 1985). A similar result was
obtained in healthy individuals after ingestion of 400 mg thalidomide tablets where in vitro
stimulation of PBMC with staphylococcal enterotoxin B (SEB) or anti-CD3 antibody resulted in
a significant enhancement of IFN-γ (Verbon, A. et al, 2000).
Thalidomide is also shown to slightly enhance the LPS-induced production of IL-10 by
PBMC from healthy volunteers (Corral, L.G. et al, 1999).
1.6.5.2.3 Effect on Plasma Cells and Antibody Production
Although formation of complexes between M. leprae antigens and their corresponding
antibody is described as an initial event in ENL, not much work has been done regarding the
effect of thalidomide on humoral immune responses. Production of primary IgM response to
sheep red blood cells (sRBC) was suppressed in Swiss Webster mice fed with a thalidomide
containing diet for 5 to 7 days prior to sensitization with sRBC; whereas, assessment of
secondary humoral immune response revealed no effect of thalidomide on anti-sRBC IgG. In this
same study, a marked reduction in serum IgM was also demonstrated in LL patients treated with
both thalidomide and dapsone compared to healthy individuals, untreated active LL patients as
well as dapsone treated patients (Shannon, E.J. et al, 1981). An opposite finding was reported in
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another study where B6C3F1 mice were treated with thalidomide and sensitized with sRBC
intravenously (i.v.). Evaluation of direct anti-sRBC plaque forming cells indicated significant
enhancement in spleen IgM level due to thalidomide treatment (Karrow, N.A. et al, 2000). The
difference of these two works was the method of thalidomide preparation, administration and
dose used. In the study by Shannon et al 1981, thalidomide was incorporated into a powdered
diet at 0.03% w/w which is the concentration required to achieve 0.84 µg/ml, an amount
equivalent to plasma thalidomide level obtained after intake of a100 mg tablet in humans. While
Karrow et al mixed thalidomide with water and injected mice by the i.p route at 30-150 mg/kg.
1.6.5.2.4 Effect on Lymphocyte Surface Expression Molecules
Patients experiencing ENL have an increase in CD4+ cells in blood as well as in skin
lesions (Modlin, R.L. et al, 1986). Thalidomide administration in vivo resulted in alteration of
the ratio of CD4+: CD8+ cells in blood of healthy individuals (Gad, S.M. et al, 1985). A
reduction in the total CD4+ cells and an increase in CD8+ cells were observed in thalidomide
treated ENL patients (Shannon, E.J. et al, 1992). Treatment of ENL patients with thalidomide
resulted in a prompt reduction in CD4+ T-cells in lesions. A reduction in the expression of MHC
Class II antigen and ICAM-1 by epidermal keratinocytes was also reported (Sampaio, E.P. et al,
1993). In vitro, treatment of PBMC with thalidomide and analysis of the expression of cell
surface markers like CD2, CD4, CD5, CD8, HLA-A, B, C and HLA-DR molecules revealed no
significant change (Shannon, E.J. et al, 1994). In HIV-infected individuals, treatment with
thalidomide resulted in marked increase in soluble CD8 antigen in plasma while no change was
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observed in soluble CD4 antigen. No significant difference was detected in CD4+ as well as
CD8+ T-cell subsets between thalidomide treated group and placebo (Haslett, P.A.J. et al, 1998).
1.7 Thalidomide in Cancer
The immunosuppressive properties of thalidomide have led investigators to test this drug
in the treatment of cancers as early as in the 1960’s. The interest in the therapeutic potential of
thalidomide in oncology quickly faded away as no dramatic effect was seen. Recently this
interest was rekindled when thalidomide’s anti-angiogenic activity was demonstrated (D’Amato
J.R. et al, 1994). Angiogenesis or the formation of new blood vessels from already existing ones
is crucial for the growth of tumors and for metastasis (Gupta, M.K. and Qin, R.Y., 2003).
Several studies of thalidomide in the treatment of various cancers have been carried out.
Multiple myeloma (MM) is one example with a dramatic response in patients that are refractory
to conventional therapy (Singhal, S. et al, 1999; Tosi, P. et al, 2002). This drug recently received
approval from the governments of Australia and New Zealand for the treatment of refractory
multiple myeloma (www.Celgene.com).
In MM, increase in bone marrow (BM) angiogenesis and an elevated BM plasma cell
labeling index are associated with disease progression and poor prognosis. Conditioned medium
of plasma cells isolated from MM patients showed a highly pronounced angiogenic activity in
chick embryo chorioallantoic membrane, an enhanced chemotaxis and proliferation of
endothelial cells (HUVEC) (Vacca, A. et al, 1999).
Malignant cells in MM are shown to secrete angiogenic cytokines known as endothelial
growth factor (VEGF) and basic fibroblast growth factor (bFGF). VEGF is a potent inducer of
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vascular permeability and a potent mitogenic activator of endothelial cells (Bellamy, W.T. et al,
1999). Stimulation of bone marrow stromal cells from multiple myeloma patients with VEGF is
shown to enhance the secretion of IL-6 a potent growth factor of myeloma cells. IL-6 is also an
inhibitor of plasma cells apoptosis (Dankbar, B. et al, 2000).
Thalidomide inhibited bFGF-induced angiogenesis in a rabbit cornea micropocket assay
(D’Amato, J.R. et al, 1994). Successful treatment of refractory MM patients with thalidomide
was demonstrated to be associated with a reduction in plasma VEGF (Kakimoto, T. et al, 2002).
Thalidomide also suppressed the proliferation of HUVEC and inhibited the production of TNF-α
by these cells (Moreira, A. et al, 1999).
Interaction of integrins with the extra-cellular matrix of endothelium is important in
endothelial cells survival, proliferation and migration during angiogenesis. The ability of
thalidomide to suppress the β3 subunit of the αvβ3 integrin and to inhibit the release of FGF,
which can stimulate the production of this integrin, suggests that thalidomide might modulate the
expression of this integrin on endothelial cell surfaces (reviewed by Stephen, T.D. et al, 2000).
But the inconsistent decrease in BM microvessel density (MVD) observed after treatment
in MM patients (Kumar, S. et al, 2002a) has led to uncertainties regarding the importance of
angiogenesis in MM. This has led to investigations of other possible anti-tumor mechanism of
thalidomide beside its anti-angiogenic effect (Kumar, S. et al, 2002b). Alternative anti-MM
mechanisms such as the induction of plasma cell apoptosis, inhibition of TNF-α secretion by
bone marrow stromal cells, modulation of T-cell immune response and induction of NK-cell
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mediated lysis of malignant cells have all been investigated (Reviewed by Tosi, P. and Cavo, M.,
2002).
In other hematological malignancies like acute myelogenous leukemia and non-Hodgkins
lymphoma, thalidomide resulted in complete or partial response rates ranging from 20%-40%. In
solid tumors like prostate, renal, brain cancers and Kaposi’s sarcoma, treatment with thalidomide
resulted in a response rate ranging from 6 % to 47% (Kumar, S. et al, 2002a).
1.8 Aim
It has been almost 40 years since Professor Sheskin discovered thalidomide to be an
effective drug for the treatment of ENL. Since that discovery, thalidomide has been used with
successes and failures in the treatment of a variety of inflammatory condition especially those
refractory to standard treatment with anti-inflammatory drugs.
A precise mechanism of action for thalidomide is still lacking. Research efforts have
pointed towards various possibilities but it has mostly been very hard to reproduce reported
findings. The major sources of variation are the methods of drug preparation employed by each
lab and the in vitro concentrations utilized. Thalidomide is poorly soluble in water and once in
solution it quickly hydrolyses to different metabolic products.
The objective of this study is to assess possible mechanisms of action of thalidomide by
using a method of drug preparation that ensures minimum hydrolysis. The concentration of
thalidomide used was within the range of physiological level achieved after ingestion of a 400
mg tablet.
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The controversial effect of thalidomide on primary T-cell response is rarely investigated
in leprosy patients. In the first part of this work (part I), the effect of thalidomide on the immune
response of PBMC from leprosy patients with or without reaction was investigated. The second
part of this study (part II) assessed the effect of thalidomide on TNF-α production in patients
with reversal reactions (RR). Although TNF-α level is elevated in RR patients, thalidomide has
no therapeutic effect on this condition. This work was based on a finding from part I where
thalidomide enhanced the production of TNF-α by PBMC from patients with borderline
tuberculoid leprosy experiencing RR (BTRR) stimulated with integral M. leprae. This finding
was further investigated by using a statistically determined sample size of untreated RR patients.
The production of TNF-α by PBMC stimulated with mycobacterial antigens and treated with
thalidomide in vitro was quantitated at protein as well as mRNA levels.
Thalidomide is shown to work in various inflammatory conditions while a convincing
mechanism for its anti-inflammatory mechanism is still lacking. As the third chapter of this study
(part III), the effect of thalidomide on the integrity of erythrocytes, PMNs and THP-1 cells
membranes was studied.
The last part of this study (part IV) assessed the anti-microbial action of thalidomide on
intracellular M. leprae. Although some speculations exist regarding the direct effect of
thalidomide on M. leprae, no work has been done so far to prove or disprove this. Intracellular
bacilli in resting as well as activated mouse peritoneal macrophages were treated with
thalidomide and the viability of M. leprae was investigated by radio-respirometric assay.
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CHAPTER 2 THE EFFECT OF THALIDOMIDE ON THE IMMUNE RESPONSE OF
CELLS FROM LEPROSY PATIENTS
2.1 Introduction
Leprosy is a chronic skin disease characterized by episodes of reactions. The cause of these
reactions is unknown. They may occur during the normal course of the disease, during treatment
and even after treatment when the patient is bacteriologically negative. They are classified as
type I /reversal reactions (RR) or type II/ erythema nodosum leprosum (ENL). Although these
reactions have different clinical manifestations, they share a similar immunological profile. The
immune response in acute ENL (Laal, S.S. et al, 1985), as well as in acute RR (Bjune, G. et al,
1976), is characterized in vitro by an enhancement in lymphocyte blast transformation to M.
leprae antigen (s). These changes indicate the presence as well as the emergence of antigenreactive-T-cells in leprosy patients that are normally anergic to M. leprae.
Among healthy individuals (Haslett, A.J.P. et al, 1998) and HIV positive patients
(Shannon, E.J. et al, 2000), thalidomide has a stimulating effect on the ability of mitogen and
antigen simulated T-cells to synthesize IL-2. Since this cytokine is important in the evolution of
events that culminate in the proliferation of lymphocytes, an objective of our study was to
determine if thalidomide could modify lymphocyte blast transformation to M. leprae antigens.
The mononuclear cells from patients attending the clinic at All Africa Leprosy,
Tuberculosis and Rehabilitation Training Center (ALERT) for treatment of their leprosy or
reactional episodes were exposed to thalidomide and to integral M. leprae, or antigens prepared
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by sonication of integral M. leprae after depletion of lipids (a modified DHAR antigen), or to
PPD prepared from M. tuberculosis. After 4 days in culture, the cells were pulsed with 3Hthymidine and on day 5 the amount of tritiated thymidine incorporated by the cells was
determined.
2.2 Materials and Methods
2.2.1

Study Subjects
Ethiopian healthy staff employed at Armauer Hansen Research Institute (AHRI) (N=11),

who are in frequent contact with leprosy and tuberculosis patients, and leprosy patients admitted
to ALERT hospital for treatment of leprosy (N=33) were enrolled in the study. Fourteen of the
patients were classified as having borderline tuberculoid leprosy (BT), eleven BT patients were
experiencing reversal reaction BT/RR, and 8 patients with ENL. All of the ENL patients
included in the study were being treated with steroids. This might have hindered the in vitro
immune responses of mononuclear cells isolated from these patients.A signed written consent
was obtained from each patient. All patients were evaluated by history and physical examination
prior to preparation of mononuclear cell cultures.
Table 2.1. Characterization of study groups
Sex
MDT*
Anti-inflammatory+
Male
Female
Healthy contacts N=11 25-56
7
4
0/11
0/11
BT N=14
13-77
6
8
1/14
1/14
BT/RR N=11
15-72
5
6
2/11
7/11
ENL N=8
15-52
4
4
4/8
7/8
* World Health Organization recommended multi-drug regimen, + Prednisone
Age Range
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2.2.2

Thalidomide
Thalidomide was kindly provided by Dr. K. Zwingenberger (Grünenthal GmbH,

Stolberg/Rhineland, Germany). The drug was dissolved in dimethylsulfoxide DMSO (Sigma,
USA) and, within 5-10 min after diluting it in RPMI, it was added into appropriate wells.
Thalidomide was used at 4.0 µg/ml in the cultures with a final concentration of DMSO of 0.25%
v/v in thalidomide and control cultures.
2.2.3

Antigens Prepared from Mycobacteria

2.2.3.1 Mycobacterium Tuberculosis
PPD RT 23 was kindly provided by Statenseruminstitut, Copenhagen, Denmark. The
preservative-free PPD was diluted in RPMI to contain 20 µg/ml and distributed in wells in a
volume of 50 µl for a final concentration of 5.0 µg/ml.
2.2.3.2 Mycobacterium Leprae
The antigens from M. leprae were prepared at the National Hansen’s Disease Programs,
Laboratory Research Branch, Immunology Lab, Baton Rouge La. Integral M. leprae (acid-fastbacteria, AFB) was isolated from the tissue of nude mice infected with M. leprae. The tissue was
aseptically removed from footpads of infected mice, and homogenized in 7H12 medium. The
homogenate was centrifuged at 30 x g for 15 minutes (min). The pellet was discarded and the
supernatant centrifuged at 2450 x g for 45 min. The pellet was suspended in 20 ml of 0.1N
NaOH. After 10 min, the alkali treated material was centrifuged at 2100 x g for 30 min. The
pellet was washed twice with pyrogen free distilled water and suspended in pyrogen free distilled
water. One half of this preparation was frozen and used as the integral M. leprae (AFB). The
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other half was prepared, as follows, for the DHAR antigen. Integral M. leprae was centrifuged at
450 x g for 30 min. The pellet was suspended in 6 ml of chloroform and dried using nitrogen gas.
The dried fraction was suspended in 6 ml of ether and centrifuged at 450 x g for 30 min. The
supernatant was discarded and the bacteria suspended in ether and transferred to an agate mortar
and worked to dryness with a spatula. The dried bacilli were suspended in 5.0 ml of pyrogen free
distilled water, and disrupted by sonic oscillation, on ice, for 15 min at 30% duty cycle
(Untrasonic Homogenizer 4710, Cole-Palmer Inst. Co., Chicago). The integral M. leprae were
enumerated and numbers adjusted to contain 100 AFB bacilli/ 50 µl / 1 mononuclear cell. The
DHAR preparation was assayed for content of proteins (DC Protein Assay, Bio-Rad), and added
to the cell cultures in a volume of 50 µl. The final concentration was10 µg of protein /ml.
2.2.4

Cell Cultures
Mononuclear cells were isolated from 30-40 ml of blood collected in Na-heparin-treated

vacuum tubes. The blood was diluted to twice its volume with RPMI-1640 and centrifuged on
Ficoll-Paque (Pharmacia, Uppsala, Sweden). The mononuclear cells were harvested and washed
three times in RPMI-1640 (Flow Labs, Irvine, UK). The cells were adjusted to contain 2 x 106
cells per ml RPMI-1640 that had been supplemented with 2 mM L-glutamine, 100 U/ml
penicillin, 100 µg/ml of streptomycin and 10% v/v fetal calf serum (Sigma) (RPMI-10%). One
hundred µl of RPMI-10% containing 2 x 105 mononuclear cells was added into flat-bottom wells
of a 96-well plate. The control cultures and cultures not treated with thalidomide received 50 µl
of RPMI-10% with DMSO at 1% v/v. The cultures treated with thalidomide received 50 µl of
RPMI-10% with DMSO at 1% v/v and thalidomide. The final concentration of unhydrolyzed
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thalidomide was 4.0 µg/ml. The final concentration of DMSO in all cultures was 0.25% v/v.
The Control cultures, not stimulated with antigen, received 50 µl of RPMI-10%. The cultures
stimulated with antigens received 50 µl of RPMI-10% containing DHAR antigen, or integral M.
leprae, or PPD (as described above).
2.2.5

Assay for Lymphocyte Blast Transformation
The cells were incubated at 5% CO2 in a high humidity, 370C incubator. Culture

systems were set up under two different conditions. One group, at the initiation of the 5-day
culture period, received 4.0 µg/ml of thalidomide (1X). Another set of cultures, to insure a source
of unhydrolyzed thalidomide during the pulse with 3H-thymidine, received 4.0 µg/ml of
thalidomide for the second time on day 4 (2X). On day four in the 2X thalidomide treated
cultures, the concentration of unhydrolyzed thalidomide was estimated to be 4.0009 µg/ml with
94 ng/ml of residual unhydrolyzed thalidomide remaining after the first 4 days in culture and the
additional thalidomide added for the second time. This calculation was based on the estimated t½
of 8.0 hrs for thalidomide in tissue culture medium at 370C (Gunzler, V. et al, 1986).
On day 4, the cultures were pulsed with 1µCi per well of H3-thymidine (Boehringer
Mannheim, Germany). After 18 hours, cells were harvested on filters and the amount of
radioactive thymidine incorporated into cellular DNA was determined using a Rack-β Liquid
Scintillation Counter (LKB, Pharmacia, Uppsala, Sweden). The results were expressed as
stimulation index (SI), which is the mean counts per minute (CPM) from three replicate cultures
of the mycobacterial antigen alone or the mycobacterial antigen + thalidomide treated cells
divided by the CPM of cultures not receiving antigen or thalidomide.
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2.2.6

Determination of TNF-α
On day 4, prior to the addition of thalidomide, 50 µl of supernatants was collected from

each culture and frozen for later analysis of TNF-α. Commercial ELISA reagents were
purchased (R&D Systems, Minneapolis) and used according to the manufacturer’s specifications.
The amount of TNF-α in each sample was determined from the standard curve using the
program KCjunior Version 1.31.2 (Bio-Tek Instruments Inc, Vermont). The concentrations of
TNF-α in cultures were expressed in ng/ml.
The percentage suppression of TNF-α was calculated from the following formula:
% Suppression= [1- (TNF-α in thalidomide treated wells)] x 100
TNF-α in untreated cultures
2.3 Results
2.3.1

Proliferative Responses in the Absence of Thalidomide
The modified DHAR and M. leprae antigen preparations were titrated for their ability to

stimulate mononuclear cells to incorporate 3H-thymidine as described previously (Shannon, E.J,
et al, 1984). Using mononuclear cells from two healthy lepromin and PPD positive individuals,
the DHAR antigen preparation stimulated the cells at 10 µg/ml. After exposing the cells to a ratio
of 1:1 or 10:1 or 100:1 M. leprae acid fast bacteria (AFB): mononuclear cells, the maximum
stimulation with integral M. leprae was observed at a ratio of 100 AFB to 1 mononuclear cell
(data not shown).
The mononuclear cells from the healthy staff, BT and BT/RR, in the absence of
thalidomide, responded to the three antigen preparations with the rank of response to PPD >
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DHAR> AFB. The patients in the ENL group were not stimulated as well to the M. leprae
antigens.
2.3.2

Effect of thalidomide on Proliferative Responses
Thalidomide (1X and 2X) did not alter the lymphoproliferative response to the

mycobacteria antigens in the BT, ENL and healthy groups.
Thalidomide (2X) empowered the mononuclear cells from the BTRR patient group to
incorporate [H3]-thymidine when stimulated with DHAR (Wilcoxon signed rank test p= 0.01)
compared to thalidomide untreated cultures (Figure 2.1)
Among the thalidomide 2X treated healthy cells, the addition of thalidomide for the
second time resulted in a suppression of cell proliferation in response to PPD and AFB compared
to thalidomide untreated cultures. This was shown by the significant decrease in SI (p=0.02 for
PPD and p=0.01 for AFB). For the rest of the groups, replenishment of thalidomide in cultures
did not affect the SI (Figure2.1).
2.3.3

Effect of Thalidomide on Synthesis of TNF-α
Thalidomide resulted in a significant suppression of TNF-α production in culture

supernatants from cells from healthy staff exposed to the modified DHAR antigen (p=0.0312)
(Figure 2.2). A mixed effect was seen for the other groups with a trend of suppression in most
cases. It is interesting to note that among the BT/RR study group, four of seven patients cells
were stimulated to produce TNF-α when incubated with integral AFB and Thalidomide (Figure
2.2).
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Figure 2.1. The Effect of Thalidomide Added at the Initiation of Incubation Period (1x) and
Thalidomide Added a Second Time 24 hours Prior to Termination of 5 days Cultures (2x).
P value derived from Wilcoxon signed rank test. A=PPD, No Thalidomide; A'=PPD +
Thalidomide (1x or 2x); B=Dharmendra, No Thalidomide; B'=Dharmendra + Thalidomide (1x or
2x); C=Integral M. leprae, No Thalidomide;C'=Integral M. leprae + Thalidomide (1x or 2x)
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Figure 2.2 Effect of Thalidomide on TNF-α Production. Culture supernatants, from cells
treated with thalidomide and antigen or DMSO and antigen, were used in ELISA to measure
TNF-α levels. Values in pg/ml were used in the following formula to calculate percent
suppression.
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2.4 Discussion
In diseases like leprosy, where cell mediated immunity (CMI) plays an important role in
protection as well as in development of reactions and subsequent complications, the in vitro
response of lymphocytes from patients against mycobacterial antigens is correlated well with the
clinical manifestations (Myrvang, B. et al, 1973). We studied the effect of thalidomide on the
lymphocyte blast transformation of cells from leprosy patients with or without reactions in
response to stimulation with mycobacterial antigens.
In vitro studies on the immunomodulatory properties of thalidomide have for the most
part been based on mitogen stimulated cells from healthy individuals. Primed antigen-specific
cells from patients may give a completely different picture. The direction of the differentiation of
naïve T-cells mainly depend on the dose and type of antigens and on the surrounding cytokines
microenvironment. In this study we used mononuclear cells from patients harboring and
sensitized to leprosy bacilli.
Type I reaction in leprosy is characterized by a sudden increase in cell mediated
immune response to M. leprae antigens (Bjune, G. et al, 1976). Our results show proliferation of
BT/RR patients’ cells in response to all three antigens compared to unstimulated controls.
However thalidomide failed to alter the in vitro proliferative response of the same patients
against mycobacterial antigens.
ENL patients’ cells have been reported to incorporate 3[H] thymidine in response to
soluble and integral M. leprae antigens (Laal, S.S. et al, 1985). Although significant, this
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response was relatively lower to that observed in tuberculoid leprosy patients. The ENL patients
included in our study did not respond well to the M. leprae antigen preparations. These patients
were being treated with prednisone (some as much as 30 mg per day) and were probably in a
hyporeactivity or anergic phase usually observed in post-treatment of ENL.
The DHAR treatment of mycobacteria is thought to improve the antigen recognition and
immune cell response without affecting the antigenic constituents of the bacilli. This is well
confirmed in our study where the response to DHAR antigen, be it in healthy staff or BT and
BT/RR leprosy patients, is relatively better than that to integral bacilli.
Thalidomide has been previously shown to enhance the DTH response to a challenge
dose of PPD in individuals with PPD skin test positivity (Tramontana, J.M. et al, 1995). In vitro,
the drug had been shown to increase synthesis of IL-2 in PPD positive individuals (Shannon, E.J.
et al, 1995). In our study, thalidomide facilitated the response against DHAR in BTRR patients.
In various in vitro studies, the effect of thalidomide on the ability of antigen or mitogen
stimulated cells to incorporate 3[H] thymidine is controversial. Among healthy PPD positive
individuals in Mexico, it was found that thalidomide or metabolites of thalidomide did not alter
the ability of cells stimulated with PPD to incorporate 3H- thymidine (Santos-Mendoza, T. et al,
1996). Whereas, another study showed that the drug enhances the proliferation of TB and HIV
co-infected patient’s cells stimulated with PPD (Bekker, L.G. et al, 2000). One possible
explanation for such inconsistencies is the extremely quick hydrolysis of thalidomide. Even in a
physiological environment like blood, thalidomide quickly hydrolyses. This characteristic of
thalidomide is even faster at pH 7.0 to 7.5 (Ericsson, T. et al, 1998). The type of solvent used,
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incubation times and pH of media determine the extent of hydrolysis and the type of metabolite,
which will predominate in the assay (Shannon, E.J. et al, 1997). Our data might be the
summation of the actions of different hydrolysis products of thalidomide.
Parallel to the proliferation assay, the effect of thalidomide on the level of TNF-α was
also assessed. Suppression of TNF-α was exhibited in healthy contacts in response to DHAR
antigens.
Despite several studies conducted for over a quarter of a century, thalidomide’s
mechanism of action in arresting ENL is still unknown. This lack of understanding is
accentuated by the uncertainties that still remain today about the factors which cause ENL.
Treatment of a given clinical condition with thalidomide may be associated with a
decrease in TNF-α like in ENL (Sampaio, E.P. et al, 1992) or an increase in TNF-α like in
aphthous ulcers (Jacobson, J. et al, 1997). In a trial involving the use of thalidomide to treat toxic
epidermal necrolysis, the work was discontinued due to an elevated drug-related toxicity. TNF-α
levels were elevated in the patients who received thalidomide compared to the placebo group
(Wolkenstein, P. et al, 1998). Comparison of prednisone, pentoxifylline and thalidomide in the
treatment of ENL revealed that although thalidomide is the most effective drug to relieve this
condition, prednisone suppresses TNF-α more than thalidomide. The level of TNF-α detected in
ENL is so low that the authors suggested that this cytokine might not be the only factor
responsible for the pathology of ENL (Moreira, A. et al, 1998). The most convincing evidence
that TNF-α is not the sole cytokine targeted by thalidomide in ENL is the observation that this
drug is not an effective treatment for reversal reaction (Hastings, R.C. et al, 1985). The
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pathology of RR, even more so than in ENL is associated with an increase in TNF-α protein and
TNF-α mRNA in the skin and peripheral nerves (Naffs, B., 1994; Khanolkar-Young, S. et al,
1995).
With the exception of cells from ENL patients, a fairly good stimulation in the presence
of all three mycobacterial antigens was obtained without thalidomide treatment. Thalidomide
resulted in a significant suppression in healthy controls in response to PPD and AFB antigens.
In order to adjust for drug hydrolysis, thalidomide was added in cell cultures a second
time. This replenishment caused an enhanced response to DHAR in the BTRR group whereas no
effect was seen in the other groups.
TNF-α production was suppressed only in the healthy control group in response to
DHAR antigen. In the BT/RR groups, in four of the seven patients an enhancement of TNF-α
production was observed in cells stimulated with integral M. leprae. Additional work is needed
to confirm this interesting finding.
Overall a clear picture of the immuno-modulatory effect of thalidomide in leprosy was
not obtained. ENL is one of the immune complications where thalidomide works best. With the
presently growing number of indications for thalidomide, another approach, like phenotypic
analysis of cell surface molecules, might result in a clearly demarcated effect to elucidate the
mechanism of action of this drug in ENL. This will provide background information for the
synthesis of the best analogue with minimal side effects.
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CHAPTER 3 THE EFFECT OF THALIDOMIDE ON THE EXPRESSION OF TNF-α
α
MRNA AND THE SYNTHESIS OF TNF-α
α IN CELLS FROM LEPROSY PATIENTS
WITH REVERSAL REACTION
3.1 Introduction
Leprosy is a spectral disease characterized by the severe form of lepromatous leprosy (LL)
at one end of the spectrum and the milder tuberculoid leprosy (TT) at the other. Borderline
leprosy patients lie between LL and TT and are immunologically unstable (Hastings, R.C.,
1985). This group of patients has a tendency to downgrade or upgrade their immune response to
M. leprae with a consequence of adverse reactions.
Reactions associated with an upgrading in the immune response to M. leprae are known as
reversal reactions (RR). Symptoms of RR include inflammation of pre-existing lesions and acute
neuritis with risks of permanent disability. The other type of immunological reaction in leprosy,
known as erythema nodosum leprosum (ENL), is mainly confined to LL patients. ENL is
manifested by the appearance of crops of tender erythematous nodules, neuritis and systemic
symptoms like fever, myalgia and general malaise (Ridley, D.S., 1969).
Common to both RR and ENL is a transient enhancement in cell-mediated immunity
towards M. leprae (Bjune, G. et al, 1976; Laal, S. et al, 1985); an elevated production of TNF-α
(Sarno, E.N. et al, 1991; Khanolkar-Young, S. et al, 1995; El-din, A. et al, 1998), with TNF-α
reported to be even more elevated in RR (Gru, G. et al, 1992).
Thalidomide is the drug of choice for the treatment of ENL, but it lacks any effect in the
treatment of RR (Hastings, R.C., 1985). Thus the beneficial effect of thalidomide in ENL, which
has been mainly attributed to an inhibition of TNF-α, does not explain why the drug is not
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equally successful in the treatment of RR. We observed, among 4 of 7 steroid-treated RR
patients, that thalidomide enhanced TNF-α when PBMC cultures were stimulated with integral
M. leprae antigen (AFB) (Tadesse, A. et al, 2003). This study is an extension encompassing a
larger non-steroid treated population of patients and also assesses mRNA expression for TNF-α
in the cultured cells.
PBMC from a group of 68 RR patients and two control groups were treated with
thalidomide and stimulated with integral γ-irradiated M. leprae (AFB), a cytosolic preparation
from M. leprae (MLSA) and DHAR antigen. Lymphocyte proliferation was determined by
incorporation of 3H-thymidine; TNF-α was measured by ELISA, and TNF-α mRNA was semiquantitated using reverse transcription polymerase chain reaction (RT-PCR).
3.2 Materials and Methods
3.2.1

Study Subjects
Based on previous observations with 4 of 7 RR patients having an enhanced TNF-α

production due to thalidomide (Tadesse, A. et al, 2003), The sample size was calculated with a
10% margin of error and a 90 % confidence level to be 68. The two control groups used were: 12
borderline leprosy patients without reversal reactions (BT, BB and BL), and 15 healthy
individuals with frequent contact with leprosy and tuberculosis patients. Patients were attending
the clinic at All Africa Leprosy Rehabilitation and Training Center (ALERT). Those
experiencing RR had blood drawn immediately upon admission and prior to treatment with antiinflammatory drugs. The subjects were informed about the purpose, possible risks and benefits
of the study and a written signed consent was obtained from each subject. Only adults of 18
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years and above were enrolled in the study. All patients were evaluated by history and physical
examination and the clinical characteristics of each patient were recorded in table 3.1.
Table 3.1. Characterization of Study Groups
Age Range
Patients with RR
BT/RR
Borderline lepromatous (BL/RR)
Lepromatous (LL/RR)
Patients without RR (Control 1)
Mid-borderline (BB)
BT
BL
Neural leprosy
Healthy Individuals (Control 2)

3.2.2

Sex
Male

Total
Female

18-65
18-70
18-65

15
26
3

17
17
0

22
43
3

55
21-73
19-55
60

1
3
5
1

0
0
2
0

1
3
7
1

24-45

9

6

15

Thalidomide
Thalidomide (kindly provided by Celgene, Warren, New Jersey) was dissolved in

dimethylsulfoxide (DMSO). Within 5-10 min after preparation, dilutions were made in complete
RPMI. As previously described, a concentration of 4.0 µg/ml of thalidomide was used (Tadesse,
A. et al, 2003). [This concentration of thalidomide best approximates the area under the curve
where thalidomide has been used effectively in the treatment of a variety of inflammatory
conditions (Erikson, T., 1997)]. A concentration of 0.25% v/v of DMSO was maintained in all
drug-treated and control wells.
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3.2.3

Antigens
γ-irradiated integral M. leprae (AFB) and a cytosol fraction of M. leprae (MLSA) were

kindly provided by an NIH awarded contract to Colorado State University (Department of
Microbiology, CSU). The γ-irradiated bacteria were used at a final concentration of 25 µg/ml and
the cytosol fraction of M. leprae (MLSA) was used at a final concentration of 25 µg/ml.
The DHAR (DHAR) antigen was prepared from M. leprae at the Laboratory of the National
Hansen’s Disease Programs in Baton Rouge, Louisiana as described previously (Tadesse, A. et
al, 2003). Based on a determination of protein content, a final concentration of 5µg/ml was used
in cultures.
Purified protein derivative PPD RT23 (Statens Serum Institut, Copenhagen, Denmark)
contained a final concentration at 10µg/ml in cultures. Phytohemagglutinin (PHA) (Sigma, Saint
Louis MI) was used at 10 µg/ml.
3.2.4 Cell Cultures
Thirty ml of blood was collected from the leprosy patients and controls. PBMC were
isolated by gradient density centrifugation. Briefly, the blood was diluted with an equal volume
of RPMI-1640 (Flow Labs, Irvine, UK) and centrifuged on Ficoll-PaqueTM (Amersham
Biosciences AB, Uppsala, Sweden). Mononuclear cells were harvested and washed twice with
RPMI-1640. The cell pellet was resuspended in complete medium (RPMI-1640 supplemented
with 10 % fetal calf serum, 2mM glutamine, 100 µg/ml streptomycin and 100 U/ml penicillin)
and cells were adjusted to contain 2 x 106/ml. One hundred µl of cells was added per well into
tissue culture plates. The cultures treated with thalidomide received 50 µl thalidomide dissolved
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in DMSO and further diluted with complete media. The control cultures, not treated with
thalidomide, received 50 µl of complete RPMI containing DMSO. The final concentration of
thalidomide was 4.0 µg/ml and the final concentration of DMSO in all cultures was 0.25% v/v.
Wells stimulated with antigens received 50 µl of the above-described antigens while control
wells received 50 µl of complete RPMI.
3.2.5 Assay for Lymphocyte Blast Transformation
The cell cultures were incubated at 5% CO2, high humidity and 370C. For cells
stimulated with mycobacterial antigens the cultures were incubated for 5 days; whereas, the
cultures stimulated with PHA were incubated for 3 days.
On day four (day two for PHA treated cultures), cells were pulsed with 2µCi per well of
H3-thymidine (Amersham, Sweden). After 18 hours, the cells were harvested on filters and the
amount of radioactivity was determined using a Rack-β Liquid Scintillation Counter (LKB,
Pharmacia, Uppsala, Sweden). A stimulation index (SI) was calculated. The SI is the mean
counts per minute (CPM) from three replicate wells of antigen or antigen + thalidomide treated
wells divided by the CPM of DMSO treated wells. The following formula was used to determine
the percent suppression (% S) by thalidomide.
% S = [1- (SI of thalidomide + antigen-treated wells)] x 100
SI of DMSO+ antigen-treated wells
[When the % S is a positive number suppression occurred; whereas, a negative number indicates
enhancement].
3.2.6

Determination of TNF-α
α
Separate cultures were set in parallel for TNF-α analysis. On day 4 of incubation, 50 µl
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of culture supernatants were pooled from each of 3 wells and frozen at –700C for later TNF-α
protein quantitation. The remaining cell suspension was collected in Nunc tubes (Nalgen Nunc
International, Denmark) and snap-frozen in liquid nitrogen for determination of TNF-α mRNA
by RT-PCR.
3.2.6.1 TNF-α
α Protein Determination
A human TNF-α commercial ELISA kit (Pierce Endogen, Woburn, MA) was used to
quantitate TNF-α in culture supernatants from AFB, DHAR and MLSA treated cultures. The
provided manufacturer’s specifications were strictly followed. The amount of TNF-α in each
sample was determined from the standard curve using Genesis Lite Version 3.03 (Life Sciences
UK, Ltd). TNF-α concentration, expressed in pg/ml, was used to calculate the percent
suppression using the following formula:
% S = [1- (TNF-α in thalidomide and antigen treated wells)] x 100
TNF-α in drug free and antigen treated wells
3.2.6.2 Determination of TNF-α
α MRNA
Frozen cell pellets were thawed and total RNA was extracted by using the RNeasy RNA
isolation kit (Qiagen, gmbH, Germany). The RNA was resuspended in RNAse free water and the
concentration was determined by spectrophotometer at 260 nm. The total RNA per each sample
was used to synthesize complementary DNA (cDNA) using the Omniscript Reverse transcription
kit (Qiagen, gmbH, Germany). The Reverse transcription (RT) mix consisted of 2 µl 10x buffer,
2 µl dNTP mix, 2 µl oligodT primer, 1 µl RNAse inhibitor and 1 µl Omniscript reverse
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transcriptase. The reaction was allowed to proceed in a Multi-block systems thermal cycler
(Hybaid, Germany) at 370C for 1 hour, 93 0C for 5 minutes and kept at 40C.
The newly synthesized c-DNA was transferred to a sterile tube. A 1:10 dilution of the cDNA was used to measure the concentration of nucleic acids at 260 nm and to check for protein
contamination by 260/280 ratios. The c-DNA was adjusted to 0.1 µg/µl with DNAse free sterile
water. Ten µl of cDNA (1 µg) was used as template in each PCR work (Multi-block systems
software, Hybaid Germany). The TNF-α primer pair sequence (Johnson B.J. and McMurray
D.N., 1994) 5´-CCTTGGTCTGGTAGGAGACG-3´ and 5´-CAGAGGGAAGAGTTCCCCAG
was used for amplification. Normalization was done with the housekeeping gene glyceraldehyde
3

phosphate

dehydrogenase

(GA3PD)

ATGCCAGTGAGCTTCCCGTTCAGC-3´and

(Villiger

P.M

et

al

1990)

primers

5´-

5´-TGGTATCGTGGAAGGACTCATGAC-3´.

Both TNF-α and GA3PD primers were synthesized at the Gene Lab of BioMMED, Division of
Biotechnology and Molecular Medicine (Louisiana State University, Baton Rouge, LA). The
PCR milieu for each tube consisted of 25 µl master mix (HotStatTaqTM PCR, Qiagen, gmbH,
Germany) 1.5 µl of GA3PD or 2.5 µl of TNF-α primers, 10 µl cDNA and 13 µl of sterile
distilled H2O. For TNF-α, the PCR program used was 950C 15 min 1 cycle; 940C 1 min, 620C 1
min, 720C 1 min 45 cycles; 720C 10 min final extension. For GAP3D the PCR program used was
950C 15 min 1 cycle; 940C 1 min, 620C 1 min, 720C 1 min 35 cycles; 720C 10 min final
extension. A mixture of 8 µl of each PCR product and 2 µl of loading buffer was resolved on
ethidium bromide stained 1% agarose gel. Bands were visualized by a UV transilluminator and
the gel pictures were analyzed by computer software (LabWork
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TM

Version 3.00, Upland,

California). The maximum optical density (OD Max) was used to score the relative intensity of
the TNF-α-specific bands against the glyceraldehype-3-phosphate dehydrogenase (GA3PD),
which was used as a control to normalize the cytokine signals within and between samples.
The percentage of TNF-α mRNA was calculated from the following formula:
% TNF mRNA = OD Max of TNF-α specific band of the sample x 100
OD Max of GA3PD band for the same sample
3.2.7

Analysis of Data
GraphPad Prism version 4.00 (GraphPad Software, San Diego California USA) was used

to analyze the data. Wilcoxon signed rank test was used to compare thalidomide treated to
untreated groups. Differences were considered to be significant when the p ≤ 0.05, 2-tail test.
3.3 Results
3.3.1 Lymphocyte Proliferation
Cell viability was assessed by 3-day stimulation with PHA. The CPM in the PHA
stimulated cultures ranged from 493 to 103,077 in the RR patients, from 372 to 37,216 in the BL
patients, and from 17,405 to 117,576 in the healthy individuals. Proliferation to the
mycobacterial antigens was assessed after 5 days in culture. Fifty three percent of healthy
individuals had a response with a SI above 2.0 for AFB, 93% for DHAR and 33% for MLSA. In
RR patients the proportion of responders was 13% for AFB, 47% for DHAR and 13% for
MLSA. Overall, the proliferative responses in the RR group were lower than the healthy control
group, but much higher than leprosy patients without reaction (Table 3.2.).

43

Table 3.2. Proportion of Subjects with a Stimulation Index Above the Cut-off Value of 2.0
Antigens
AFB
DHAR
MLSA

RR (n=68)
9 (13.2*)
32 (47)
9 (13.2)

No RR (n=15)
2 (16.6)
0
1 (8.3)

Healthy (n=12)
8 (53)
14 (93.3)
5 (33.3)

*

Values in bracket represent percentages

3.3.2

Effect of Thalidomide on Lymphocyte Proliferation
The SI in drug free + antigen-treated wells with the SI in thalidomide + antigen-treated

wells, inn the RR patient group thalidomide significantly enhanced proliferation in response to
DHAR (p= 0.004) and MLSA (p= 0.013); it failed to significantly stimulate proliferation in
response to AFB (p= 0.0629). Thalidomide also suppressed AFB induced proliferation among
healthy controls (P= 0.0084) (Figure 3.1). In all of the groups, thalidomide did not significantly
modify the response of PBMC to PPD (data not shown).
3.3.3

Effect of Thalidomide on the Synthesis of TNF-α
α
The TNF-α levels in drug free + antigen-treated wells with TNF-α in thalidomide +

antigen-treated wells, in all the groups, thalidomide: suppressed the synthesis of TNF-α, in
response to the antigen preparations from AFB, DHAR and MLSA (p < 0.0001) (Figure 3.2A).
A similar suppression of TNF-α due to treatment with thalidomide was seen in healthy
individuals (AFB p=0.0017, DHAR p= 0.0134 and MLSA p= 0.0266) (Figure 3.2B). For
borderline leprosy patients without RR, the suppression was significant in the AFB (p=0.031)
and MLSA (p=0.0156) stimulated groups (Figure 3.2C).
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Figure 3.1. Effect of Thalidomide on Lymphocyte Proliferation to M. Leprae
Antigens. PBMCs from leprosy patients with RR (A), patients without RR (B) and healthy
individuals (C) were incubated with mycobaterial antigens and thalidomide for 5 days. At day 4,
cultures were pulsed with tritiated thymidine. Counts per minutes were used to calculate SI,
which are then used to determine the percentage enhancement (%E) or suppression (%S) by
thalidomide.
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Figure 3.2. The Effect of Thalidomide on TNF-α
α Production. PBMCs from leprosy patients
with RR (A), with leprosy patients without RR (B) and healthy individuals (C) were stimulated
with AFB, DHAR and MLSA antigens for 4 days. Pools of 3 wells culture supernatant were used
in ELISA to quantitate the level of TNF-α. The percentage suppression (%S) and enhancement
(%E) were used as y intercepts.
3.3.4

Effect of Thalidomide on TNF-α
α MRNA Level
The TNF-α primers used were designed to span the junctions of 2 exons, making them

specific for cDNA and not capable of recognizing contaminating genomic DNA (Johnson,
B.J. and McMurray, D.N., 1994). As shown in Figure 3.3, the presence of TNF-α mRNA was
validated by the presence of a 325 bp band in the agarose gels (Wang, A.M. et al, 1989).
Although a fairly consistent cDNA band for TNF-α was detectable in almost all PBMCs in
response to all three antigens (Figure 3.4), thalidomide did not significantly influence the TNF-α
mRNA expression pattern in antigen stimulated cells (Wilcoxon signed rank test). The spread
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was more pronounced among RR patients. GA3PD gave a fairly consistent band intensity of 190
bp.
TNF-α
α

GA3PD

* CT

A

* CT A

AT D DT M MT

AT

D

DT M

MT

*

*

CT A AT D DT

CT A

M

MT

AT D DT M

MT

Figure 3.3. Effect of Thalidomide on TNF-α
α MRNA Expression. PBMC were stimulated with
antigens for 5 days. Total mRNA was extracted; c-DNA synthesized and TNF-α mRNA
expression was assessed by RT-PCR using specific primers. The housekeeping gene GA3PD
was used for normalization. Lane legend: (*) molecular mass marker 123 bp DNA ladder, (CT)
unstimulated cells + thalidomide, (A) AFB, (AT) AFB + thalidomide, (D) DHAR, (DT) DHAR
+ thalidomide, (M) MLSA and (MT) MLSA + thalidomide.
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Figure 3.4. The Effect of Thalidomide on the Expression of TNF-α
α MRNA in Antigen
Stimulated Cells. Total RNA was extracted and used to synthesize cDNA. PCR was done using
TNF-α specific primers. Values are normalized with the housekeeping gene GA3PD. A: AFB,
A+T: AFB + thalidomide(T), D: DHAR, D+T: DHAR+T, M: MLSA, M+T: MLSA+T.
3.3.5

Thalidomide-Induced Enhancement of TNF-α
α and TNF-α
α MRNA
In 11 of the 68 RR patients, stimulation of PBMC with AFB antigen resulted in enhanced

production of TNF-α (Table 3.4). These patients were of the BL/RR type with only one BT/RR
patient. The SI was also enhanced due to treatment with thalidomide except for patients 1398/02
and 360/03. Six out of 8 patients had a correspondingly enhanced expression of TNF-α mRNA.
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Table 3.4. Characteristics of the Sub-Group of RR Patients with Enhanced TNF-α
α
ID

Age

Sex

RR Type

* % E or S, SI

* % E or S, TNF-α
α

1329/02 60
F
BL/RR
-12
-12
1398/02 45
M
BL/RR
26
-6
049/03 18
F
BL/RR
-69
-4
165/03 60
F
BL/RR
-297
-6
318/03 18
M
BL/RR
-18
-1
347/03 40
F
BL/RR
-76
-28
360/03 20
F
BL/RR
8
-49
383/03 55
M
BL/RR
-109
-76
385/03 18
F
BL/RR
-109
-9
405/03 70
M
BL/RR
22
-21
422/03 32
M
BT/RR
-118
-2
% E: percent enhancement, % S: percent suppression
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* % E or S TNF-α
α mRNA

-27
Not available
-88
Not available
24
Not available
-47
-39
-13
Not available
-167

3.4 Discussion
Thalidomide has been shown to be effective in the treatment of pathologies associated with
elevated TNF-α such as ENL (Sampaio, E.P. et al, 1993), and wasting syndrome in tuberculosis
and HIV infections (Klausner, J.D. et al, 1996). This has been attributed mainly to the ability of
thalidomide to suppress TNF-α (Sampaio, E.P. et al, 1993). There are, however, conditions such
as toxic epidermal necrolysis where the rationale for using thalidomide to suppress TNF-α failed
and an enhanced production of TNF-α was reported (Wolkenstein, P. et al, 1998).
In RR, TNF-α was elevated even more so than in ENL (Gru, G. et al, 1992) in lesions as
well as in the serum, yet thalidomide lacked any effect against this condition. Previously it was
observed among steroid treated patients with RR that thalidomide induced an enhancement of
TNF-α when mononuclear cells were stimulated with integral M. leprae (Tadesse, A. et al,
2003). Non-steroid treated RR patients were studied to corroborate this observation and the
influence of thalidomide on TNF-α in RR patients cells stimulated with mycobacterial antigens
was assessed by measuring the expression of TNF-α mRNA in parallel with the synthesis of
TNF-α.
Cells stimulated with mycobacterial antigens, in the absence of thalidomide, gave an
enhanced proliferative response in RR patients compared to patients without reaction. This
confirmed the frequently described transient augmentation of cell-mediated immunity or the
enhanced delayed type hypersensitivity (DTH) response to M. leprae antigens in RR (Bjune, G.
et al, 1976; Cooper, C.L et al, 1989). Thalidomide co-stimulated the proliferative responses in
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RR patients to the MLSA and DHAR antigens, but not to the AFB. The immuno-modulatory
action of thalidomide has been shown to vary depending on the stimulant, the cells stimulated
and the signalling pathway involved. The thalidomide-induced enhancement of proliferation of
antigen specific T-cells in this study was similar to studies where PBMC were stimulated by
cross-linking of T-cell receptor with anti-CD3. In these studies, thalidomide acts as a costimulator resulting in enhanced proliferation of lymphocytes (Haslett, P.A.J. et al, 1998; Corral,
L.G. et al, 1999; Marriot, J.B. et al, 2002).
Among the RR group in response to DHAR and MLSA antigens and when comparing
antigen stimulated cultures to antigen and thalidomide treated cultures, thalidomide enhanced
lymphocyte proliferation but significantly suppressed TNF-α production. This is in contrast to a
previous report by Marriot JB et al 2002 who showed that enhanced production of TNF-α is
correlated with enhanced lymphocyte proliferation. In their study T-cells were stimulated
directly by using anti-CD3 antibody; whereas, in this study, antigens derived from M. leprae that
are likely to require processing and presentation to T-cell were.
The effect of thalidomide on the expression of TNF-α mRNA in PBMC stimulated with
the mycobacterial antigens was also assessed. Samples for the assessment of TNF-α and TNF-α
mRNA were harvested at the same time but no correlation with a correspondingly consistent
reduction of TNF-α mRNA with TNF-α was observed due to thalidomide treatment. When
purified monocytes were stimulated with LPS, Moreira A., et al 1993 showed thalidomide to
suppress TNF-α by reducing the half-life of TNF-α mRNA from 30 to 17 minutes. A likely
explanation for this discrepancy is the varying effects of thalidomide related to the dominant cell
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type and antigen used for stimulation (Marriot, J.B. et al, 2002). Alternative mechanisms of
TNF-α suppression by thalidomide are blocking of NF-kB, a transcription factor involved in the
regulation of several genes including TNF-α gene (Keifer, J.A. et al, 2001) and binding of
thalidomide to α1-acid glycoprotein, a pro-inflammatory protein that belong to the acute phase
proteins family (Turk, et al, 1996).
Previous observation made among 4 of 7 RR patients of a thalidomide-induced enhanced
production of TNF-α in response to stimulation with AFB was again observed in 11 out of 68.
When comparing the effect of thalidomide in AFB stimulated PBMCs from all 68 RR patients,
thalidomide failed to act as a co-stimulant. But, it did act as a co-stimulant in the subgroup of 11
RR patients. In systems where thalidomide acts as a co-stimulator of T-cell activation, a
subsequent induction of TNF-α was demonstrated (Marriot, J.B. et al, 2002). This co-stimulatory
property of thalidomide is dependent on IL-2-mediated signalling indicating that T-cell
activation rather than the direct effect of thalidomide resulted in increased production of TNF-α.
One proof of IL-2-mediated signalling is an enhanced stimulation index in response to AFB in 8
of these 11 RR patients. Although the level of IL-2 was not measured in this study, an
augmentation of IL-2 by thalidomide was demonstrated by Shannon et al, (Shannon, E.J. and
Sandoval, F., 1995) and confirmed by Haslett et al, (Haslett, P.A.J. et al, 1998).
Cytokine secretion by T-cells is a transient process and requires activation of T-cells.
Usually in T-cells, cytokine proteins and mRNA are not stored intra-cellularly but rather
synthesized de novo. The transcription of these cytokines genes is highly regulated with most of
their mRNAs having a short T1/2 (Lohning, M. et al, 2002). An exception to this rule is TNF-α,
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whose mRNA is stored in resting cells in an unspliced form called pre-TNF-α. T-cell stimulant
like anti-CD3 and PMA result in massive release of TNF-α, which is due to an induction of
transcription of TNF-α gene as well as enhanced splicing of accumulated pre-TNF-α mRNA
(Yang, Y. et al, 1998). Thalidomide might alter TNF-α at a post-transcriptional level by
influencing the splicing of existing pre-TNF-α mRNA. Makonkawkeyoon et al, (1993) showed
that the addition of thalidomide increased the amount of PMA-induced TNF-α mRNA in ACH-2
cells- a T-cell line. If thalidomide acts as a co-stimulator as previously reported (Mariott, J.B. et
al, 2002) it might also stabilize the mature TNF-α mRNA leading to increased production of
TNF-α.
The thalidomide-induced augmentation of TNF-α mRNA and TNF-α that was observed
in cultures was limited to stimulation with integral M. leprae (AFB). Processing of the integral
M. leprae antigen (AFB) by macrophages and Schwann cells and presentation of certain specific
peptides might be responsible for activation of T-cells and enhancement of TNF-α production in
RR.
No striking in vitro parameter that can explain the absence of an effect of thalidomide in
the treatment of RR was detected in this work. The pathogenesis of RR is the outcome of a
complex interaction of antigen specific cell mediated immune responses and non-specific antiinflammatory events. The differential expression of the M. leprae antigens lipoarabinomanan
(LAM) and phenolic glycolipd-1 (PGL-1) in lesions of RR patients (Verhagen, C. et al, 1999)
and the concordant association of lymphocyte proliferation to M. leprae with the degree of
inflammation among RR patients (Bjune, G. et al, 1976) are two examples of this complexity.
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Unique to leprosy is the homing of the bacilli into Schwann cells. These cells have been
shown to process and present M. leprae to MHC-II restricted CD4+ (Ottenhoff) and MHC-I
restricted CD8+ T-cells (Steinhoff, U. et al, 1988). This dual property of the Schwann cell makes
it a candidate for direct lysis by cytotoxic T-cell and probably explains the intense neuritis
characteristic of RR. In an experimental autoimmune encephalitis (EAE) model using rats,
thalidomide prolonged the duration of EAE and enhanced the inflammation of sciatic nerve
(Zhu, J. et al, 1998). Similar to this model of T-cell-induced neuritis, the use of thalidomide in
the treatment of RR may result in an exacerbation of the reaction.

54

CHAPTER 4 THE EFFECT OF THALIDOMIDE ON THE VIABILITY OF
INTRACELLULAR M. LEPRAE IN ACTIVATED MACROPHAGES
4.1 Introduction
Thalidomide is the treatment of choice for erythema nodosum leprosum (ENL) (Sheskin,
J., 1980). The sequence of events, which precipitate ENL as well as the exact mechanism by
which thalidomide arrest ENL has not yet been clearly delineated. The patients that may
experience ENL during the course of their disease are those in the lepromatous end of the leprosy
spectrum (lepromatous leprosy, LL and borderline lepromatous leprosy, BL) (Hastings, R.C.,
1985). These patients are characterized by the presence of precipitating antibodies in their sera
and a tremendous load of mycobacterial antigen inside macrophages (Ridley, M.J. and Ridley,
D.S., 1983). As the likelihood of an episode of ENL increases after the initiation of treatment, it
has been suggested that release of M. leprae antigens from macrophages may be a factor, which
initiates ENL (Hastings, R.C., 1985). The released antigen may then complex with antibodies,
initiating complement fixation and production of inflammatory cytokines like TNF-α.
Inhibition of TNF-α is one proposed mechanism by which thalidomide arrests ENL
(Sampaio, E.P. et. al, 1991). However in a short open clinical study comparing the effects of
thalidomide with other known inhibitors of TNF-α like pentoxifylline and prednisone, the
authors concluded that thalidomide might have other targets in ENL (Moreira, A. et. al, 1998).
Other evidence that TNF-α is not the sole cytokine targeted by thalidomide in ENL is the fact
that thalidomide is not an effective treatment for reversal reaction (RR) (Hastings, R.C., 1985).
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RR is another type of hypersensitivity reaction in leprosy where TNF-α is detected in skin and
peripheral nerve lesions (Khanolkar-young, S. et. al, 1995). Depending on experimental
conditions, and the type of cells stimulated, thalidomide may enhance or suppress the synthesis
of TNF-α (Shannon, E.J. and Sandoval, F., 1996). Previous work has recently shown that
thalidomide enhanced TNF-α in cells from RR patients stimulated with integral M. leprae
(Tadesse, A. et. al, 2003).
This report addresses a different tact in exploring the efficacy of thalidomide in treating ENL
reactions. Could thalidomide actually be inhibiting the killing and breakdown of M. leprae and
thereby inhibit the release of antigens? To study the effect of thalidomide on the fate of M.
leprae in host macrophages, the viability of M. leprae residing in thalidomide-treated normal or
IFN-γ-endotoxin activated mouse macrophages was assessed.
4.2 Materials and Methods
4.2.1

Source of M. Leprae
Freshly isolated M. leprae from footpads of nude mice was used throughout the

experiments (Ramesh, N. et al, 1991). In each of the experiments, the viability of 4 x 107 acidfast bacteria (AFB) was assessed by inoculating the M. leprae suspension into vials containing
BACTECTM PZA Test Medium (Becton Dickinson Diagnostic System, Sparks, MD). The
cumulative 14CO2 was measured daily for 7 days.
4.2.2

Mouse peritoneal macrophages
Macrophages were isolated from the peritoneal cavities of retired female Swiss Webster

breeder mice (Simonsen Labs, Gilroy, CA). Briefly, 15 ml of cold heparinized phosphate
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buffered saline (PBS) was injected into the peritoneal cavity of each mouse. The peritoneal
exudates was collected and washed. The cell pellet was resuspended in 10 ml of Complete
Medium (RPMI 1640, 50 µg/ml ampicillin, 2 mM glutamine, 10% fetal bovine serum). Cells
were counted and adjusted to 4 x 106 per ml. The cell suspension was dispensed at 0.5 ml/well in
24-well plates containing LUX ® plastic cover slips (Miles Laboratory, Naperville, IL). The
plates were incubated overnight in a humidified incubator at 37 0C, 5% CO2. Non-adherent cells
were washed off by dipping coverslips in sterile PBS and draining excess liquid on sterile
gauzes. The coverslips were placed in another 24-well plate containing 0.5ml/well Complete
Medium.
4.2.3

Treatment Conditions
Thalidomide was provided by Celgene (Warren, NJ) and was dissolved in a solution of

0.85% NaCl, pH 3.0 (Acid Saline, AS) as described previously (17). A stock solution of 50
µg/ml was aliquoted and kept in –70 0C freezer. Shortly before each experiment, dilutions of
thalidomide at concentrations of 0.625 µg/ml, 1.25 µg/ml, 2.5 µg/ml and 5 µg/ml were done in
AS. Based on the previously estimated half-life of 8.0 hrs for thalidomide in tissue culture
medium at 370C (Gunzler, V. et al, 1986), cultures were replenished with 50 µl of AS containing
thalidomide or 50 µl of AS daily to maintain an estimated concentration of ≥ 1.0 µg/ml of unhydrolyzed thalidomide in the 5 µg/ml treated cultures.
4.2.4

Activation of Macrophages - Infection - Treatment with Thalidomide
Monolayer cells on coverslips were incubated for 8 hours with 200 Units/ml of mouse

recombinant IFN-γ (R and D Systems Inc., McKinley, MN) and 2.0 ng/ml of endotoxin (Sigma,
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St Louis, MO). Coverslips were washed as described previously and placed in fresh Complete
Medium. Viable M. leprae (4 x 107) was added into the resting or activated macrophage
monolayer at an estimated 20:1 bacilli: macrophage. After an overnight incubation at 330C, nonphagocytosed bacilli were removed by washing the coverslips. The infected macrophages were
incubated with the different concentrations of thalidomide and controls. Drug and media was
replenished daily for 7 days in the non-activated cultures and 3 days in the activated cultures. A
shorter exposure to thalidomide in the activated macrophages was necessary as the cells were
observed to detach after 3 days.
4.2.5

Assessment of M. Leprae Viability: Radiorespirometric Assay
A modified Buddemeyer radiorespirometric assay was used to assess the viability of M.

leprae released from macrophage as described previously (Ramesh N. et. al., 1991). The
coverslip containing the macrophage monolayer was placed in 400 µl of 0.1 N NaOH solution.
Three hundred µl of the lysate was gently mixed and transferred to a sterile glass vial containing
4.0 ml of PZA Test Medium with 1.0 µCi of [1-14C] palmitic acid and 50 µg/ml ampicillin. The
vials with loosen cap were placed within PolyQ polyethylene vials containing a dried strip of
Whatman DE42 filter paper (Whatman, Inc., Clifton, NJ). The paper had been dipped in a
mixture of Liquifluor PPO-POPOP [2,5 diphenyloxazole-1, 4-bis (5-phenyloxazoly) benzene]
toluene concentrate (New England Nuclear, Boston, MA) Triton X-100 and 4.0 N NaOHmethanol. The strips were dried and kept at room temperature in a canister protected from light.
The PolyQ vials with tightly closed cap were incubated at 330C. The generation of radioactive
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14

CO2 was determined daily by reading in a Beckman model LS-6000IC liquid scintillation

counter. Data are presented as cumulative counts per minutes (CPM).
4.2.6

Assessment of TNF-α in Activated Macrophages
Twenty-four hours after thalidomide treatment of activated and infected macrophages, an

aliquot of the culture supernatant was removed and frozen at -70 0C. TNF-α was measured by
using a mouse TNF-α immunoassay kit according to the manufacturer’s specification
(Quantikine, R&D Systems, Minneapolis, MN). The amount of TNF-α in each sample was
determined from the standard curve using KCjunior Version 1.31.2 (Bio-Tek Instruments Inc,
Vermont).
4.2.7

Nitrite Assay
NO2- levels in culture supernatants were determined as described previously (Drapier, J.C.

et al, 1988). Briefly, Griess reagent was prepared and dilutions of NaNO2 solution were used as a
standard. All samples were assayed in duplicate. Samples were culture supernatants of activated
macrophages treated with thalidomide for 24 hours and collected as described for TNF-α. 50 µl
of standard and samples were dispensed into wells of a 96 well flat bottom tissue culture plate.
Duplicate blank wells with media alone were also included in the experiment. 100 µl of Griess
reagent was added into each well. The plate was mixed by gently tapping and incubated at room
temperature for 20 minutes. Absorbance was read at 543 nm. The amount of NO in each sample
was determined from the standard curve using KCjunior Version 1.31.2 (Bio-Tek Instruments
Inc, Vermont).
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4.3 Results
4.3.1

Assessment of Metabolic Activity of Intracellular M. Leprae
Prior to infecting the macrophages the viability of M. leprae used for each experiment

was tested by inoculating into Pyrazinamide (PZA) test medium. At day 7, the cumulative mean
+/- SD from 4 experiments was 36,344 +/- 3,801.
Bacilli recovered from non-activated macrophages had a higher 14CO2 level (CPM range
day 1- day 7:

2989 +/- 1391 to 7582 +/- 5481) compared to IFN-γ and LPS activated

macrophages (CPM range day 1- day 7: 1488 +/- 324 to 3318 +/- 1129) (Figure 4.1). The
difference between activated and resting macrophages was significant for all days except day 7
(unpaired T test, GraphPad Prism V 4.0).

Figure 2. Viability of M. Leprae in Activated Versus Resting Macrophages. Resting (open
bar) and IFN-g -LPS-activated (hatched bar) mouse peritoneal macrophages were infected with
M.leprae for 24 hours. Bacilli released from lysed macrophages were incubated in PZA test
medium and14CO2 was quantitated daily for 7 days. Mean CPM+/- SD of 3 to 8 replicates.
Unpaired t test,* p< 0.05,** p< 0.01.
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4.3.2

Effect of Thalidomide on Viability of M. Leprae
Over a 7-day period, a gradual daily increase in

14

CO2 was observed in the AS-treated

control cultures and the thalidomide-treated wells at 0.625, 1.25, 2.5 and 5 µg/ml. There was no
demonstrable titrated effect of thalidomide (data not shown). Figure 4.2 summarizes the
cumulative mean CPM +/- S.D from 3 separate experiments on day 7 for thalidomide at 5 µg/ml.
Comparison of the drug-free control group to the thalidomide treated groups in non activated as
well as activated macrophages revealed no significant difference (unpaired T test).

Figure 4.2. Effect of Thalidomide on Viability of M. Leprae Recovered From NonActivated and Activated Mouse Peritoneal Macrophages. Infected mouse peritoneal
macrophages were treated with 5 µg/ml of thalidomide (Thal 5) and acid saline (AS). Cells were
lysed and the viability of released bacilli was assessed by determining counts per minute (CPM)
of cummulative 14C02 released. Open bars represent non-activated macrophages, closed bars
represent activated macrophages. Means +/- SD from 3 separate experiments.
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4.3.3

TNF-α and Nitrite Levels in Activated Macrophages
After 24 hours exposure to thalidomide, no significant changes in TNF-α and NO2- was

observed compared to media or AS controls. Although TNF-α levels were higher in thalidomide
treated cells (24.8 pg/ml +/- 3.47) compared to AS-treated ones (18.12 pg/ml +/- 8.2), it was not
statistically significant (Figure 4.3).

Figure 4.3. Nitrite and TNF-α Levels in M. Leprae-Infected LPS-IFN-γ-Activated
Macrophages. Activated mouse peritoneal macrophages were infected with viable M.leprae and
treated with thalidomide at 5 µg/ml for 24 hours. Nitrite (A) and TNF-α (B) in culture
supernatants were quantitated. Mean and SD for 4 replicate wells controls; M= media, AS= acid
saline and T5= thalidomide.
4.3.4

Morphological Appearance of Peritoneal Macrophages
Breakdown products of thalidomide have been described to inhibit the attachment of cells

to plastic surfaces (Braun, A.G. and Weinreb, S.L., 1984). For visual inspection of attachment of
cells, coverslips from each treatment were stained with quik-Diff® (Dade Diagnostics, Aguada,
PR), dried and mounted on microscopic slides.
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The density of the cells appears to be the same in all the treated groups. Activated cells
had a spindle-like shape and are clearly different than non-activated cells. Thalidomide treated
activated macrophages were not morphologically different than AS treated activated
macrophages (Figure 4.4).

Figure 4.4. Monolayers of Mouse Peritoneal Macrophages.
(A) Media control, non-activated
(B) LPS + IFN-γ-activated and M. leprae Infected
(C) LPS + IFN-γ-activated, M. leprae infected and thalidomide-treated
(D) LPS + IFN-γ-activated, M. leprae Infected and acid saline-treated
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4.4 Discussion
In diseases like leprosy, a cell-mediated immune response plays a major role in the
outcome of infection. The key components of this response are macrophages and T-lymphocytes.
Killing of M. leprae by activated macrophages is the main mechanism of elimination of the
bacteria (Sibley, D. et al, 1987). ENL is characterized by the detection of granulated beaded
bacteria indicating a massive release of M. leprae by macrophages (Ridley, M.J. and Ridley,
D.S, 1983). Although thalidomide is an effective treatment for ENL, the mechanism by which it
alleviates this reaction is not fully understood. It is possible that drugs like thalidomide,
depending on their concentration, may enhance local production and release of TNF-α into the
microenvironment of the ENL skin lesion and facilitates remodeling of inflamed tissue. When
TNF-α is produced in lesser quantities and in a timely fashion, it mediates a variety of antiinflammatory events promoting wound healing and remodeling of injured tissue (Vlassara, H. et
al, 1988) and suppressing neutrophil migration (Otsuka, Y. et al, 1990).
The anti-inflammatory and immunomodulatory properties ascribed to thalidomide offer
multiple potential sites of action in arresting ENL. In this work we have tried to study whether
thalidomide modulates the anti-microbial action of host macrophages against intracellular M.
leprae as a possible prelude to inhibiting the release of mycobacterial antigen.
Non-activated mouse peritoneal macrophages infected with M. leprae were treated with
0.625-5.0 µg/ml of thalidomide for a week. Thalidomide failed to show a dose-response
relationship and failed to alter the metabolic activity of M. leprae in a significant manner. Higher
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concentrations of thalidomide may have shown a different result; however, the concentration of
5.0 µg/ml was, considered to be, more relevant to that achieved in the treatment of ENL.
These findings concur with previous studies on the in vitro as well as in vivo antimicrobial action of thalidomide against other pathogens. Although thalidomide was effective in
alleviating clinical symptoms associated with Mycobacterium Avium Complex (MAC) in HIV
patients (Bouza, E.R. et al, 1992), in vitro it was unable to kill laboratory-cultured strains of
MAC (Vicente, T. et al, 1993). Thalidomide is also effective against microsporidial diarrhea, but
when tested in vitro, it failed to kill intracellular microsporidia (Ridoux, O. et al, 1999). In
murine experimental tuberculosis (Moreira, A.L. et al, 1997) and BCG infection (Fazal, N.L. et
al, 1988) models, thalidomide did not significantly alter bacterial load in organs.
For efficient activation of M. leprae burdened macrophages, in addition to a primary
stimulatory signal delivered by IFN-γ a secondary signal like endotoxin is required (Krahenbuhl,
J.L. et al, 1990). The peritoneal macrophages were co-stimulated with IFN-γ and LPS. In the
absence of thalidomide, the cumulative 14CO2 from activated macrophages was higher than that
of non-activated macrophages confirming previous findings where activated mouse peritoneal
macrophages killed or inhibited M. leprae more effectively than non-activated macrophages
(Adams, L.B. et al, 2000). When tested in this activated macrophage system, thalidomide did
not modify the viability of M. leprae in a significant manner.
The effect of thalidomide on TNF-α produced in IFN-γ- LPS- activated-M. Lepraeinfected macrophages were also examined. Although statistical analyses revealed no significant
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difference between TNF–α level from thalidomide and from AS treated cells, a higher level of
TNF-α was observed in the thalidomide treated group.
Reactive nitrogen intermediates, especially nitric oxide (NO) constitute a major antimicrobial effector armature of activated mononuclear phagocytes with activities against a broad
spectrum of pathogens (Hibbs, J.B. et al, 1987). A reduction in the viability of M. leprae occurs
when activated mouse peritoneal macrophages produce a high level of NO (Adams, L.B. et al,
2000). In this study, although the level of NO2- produced was similar to that reported by others,
thalidomide failed to influence the production of this molecule.
This work showed that thalidomide does not possess a direct anti-microbial action against
intracellular M. leprae in normal or activated macrophages. Nor did it alter the production of
TNF-α and NO in a significant manner. A distinct sequence of events explaining the mechanism
of action for thalidomide to successfully treat ENL has yet to be established.
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CHAPTER 5 THE EFFECT OF THALIDOMIDE ON THE INTEGRITY OF PLASMA
CELL MEMBRANES
5.1 Introduction
The anti-inflammatory properties of thalidomide are demonstrated by its beneficial effects
in the treatment of inflammatory conditions like erythema nodosum leprosum (ENL), which may
occur in leprosy patients, and apthous ulcers which may occur in AIDS patients (Zwingenberger,
K. and Wendt, S., 1996; Tseng, S.P. et al, 1996). The sequences of events that precipitate these
inflammatory conditions as well as the molecular and biochemical basis for the antiinflammatory properties of thalidomide are not understood. A common finding in the lesions of
patients experiencing ENL or apthous ulcers is an influx of polymorphonuclear neutrophils
(PMN) (Mabalay, M.C. et al, 1964; Burns, R.A. et al, 1985). Reactive oxygen species (ROI)
produced by the PMN are important in intracellular killing of pathogens; however these ROI can
also combine with enzymes released from lysosomes causing tissue damage and inflammation of
the surrounding extra-cellular environment (Parham, P., 2000).
Stabilization of lysosomal membranes by thalidomide could be a mechanism for its antiinflammatory action in ENL. Hastings showed that in vitro thalidomide prevented the release of
B-glycerophosphatase from lysosomes isolated from rat livers. The drug was effective at
concentrations similar to those achieved in the blood of leprosy patients effectively treated for
their ENL (Hastings, R.C., 1971). Based on this interesting finding, the effect of thalidomide on
cell membrane integrity was studied.
For stabilization of erythrocyte membrane, we used a modification of Dacie’s osmotic
fragility test (Dacie, J.V., 1975). This test measures hemoglobin released from lysed RBCs after
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their exposure to hypotonic solutions of sodium chloride (NaCl). The in vitro as well as in vivo
effects of thalidomide on hemolysis of RBCs from healthy humans were investigated. To probe
the effect of thalidomide on the stability of membranes of inflammatory cells, human PMNs and
the human-monocytic cell line THP-1 were employed. The detection of lactic acid
dehydrogenase (LDH) released in culture supernatants as a result of leakage was used as an
indicator of membrane dysfunction.
5.2 Materials and Methods
5.2.1

Preparation of Thalidomide
The drug for in vitro and ex vivo use was provided by Celgene and dissolved in acid

saline (AS) as previously described (Shannon, E.J., et Al, 1997). AS was chosen as the solvent
for thalidomide rather than the commonly used DMSO. This is due to reported interference of
DMSO with cell metabolism and membrane integrity resulting in cellular damage (Penninck, F.
et al, 1983).
5.2.2

In Vitro Thalidomide Treatment
Ten ml of peripheral blood was collected in a Na-heparin vacuum tube from 12 healthy

adult volunteers by venipuncture. The blood sample was equally divided into 2 tubes. One tube
of blood was centrifuged at 913 x g, at room temperature for 10 minutes. The plasma was
removed and replaced with an equal volume of AS (normal saline, pH 3.0). The tube was labeled
Washed RBC. The second tube containing the plasma was labeled Not Washed RBC.
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5.2.3

Ex Vivo Thalidomide Treatment
Sixteen healthy male volunteers were included in this part of the study. Twelve received

drug and 4 received placebos. A blood sample was taken prior to ingestion of a 100 mg tablet
and after the subject has consumed a cumulative dose of 600 mg of thalidomide given as one 100
mg tablet every 4 hours. The blood was directly used (at 10 µl/well) in osmotic fragility
experiments.
5.2.4

Osmotic Fragility
For convenience, Dacie’s method (Dacie, J.V., 1975) of osmotic fragility was modified to

a micro-scale assay. Briefly, a 100 ml of a stock buffered NaCl solution containing 9 g of NaCl;
1.365 g of Na2HPO4 and 0.215 g of NaH2PO4.H2O was prepared. A 1% solution of buffered
NaCl was prepared by diluting the stock NaCl in deionized water. In a 96-well V-bottom
microtiter plate, the dilution scheme in Table 5.1 was used to prepare hypotonic solutions.
Table 5.1. Dilution Scheme of NaCl and Water to Give the Various % Salt Concentrations
Dilution
1
2
3
4
5
6
7
8
9
10
11
12
13
14

1% buffered NaCl (µl)
200
170
150
130
120
110
100
90
80
70
60
40
20
0

Deionized water (µl)
0
30
50
70
80
90
100
110
120
130
140
160
180
200
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Final NaCl Concentration %
1.00
0.85
0.75
0.65
0.60
0.55
0.50
0.45
0.40
0.35
0.30
0.20
0.10
0.00

The final volume in each well was 200 µl, 3 to 6 replicate wells were used for each
concentration of salt. Ten µl of ThalW or ASW or Thal or AS treated blood was added into each
well and the plate was incubated for 30 minutes at room temperature. At the end of incubation,
the plates were spun at 913 x g, at room temperature (RT) for 5 minutes. 100 µl of supernatant
was carefully transferred from each well into wells of a clean flat bottom microtiter plate. The
extent of hemolysis was determined by reading the plate in an ELISA reader (Synergy HT Multidetection microplate reader, Biotek) at 550 nm. Optical density (OD) readings were analyzed by
using the software KC4 Version 3.0 ELISA Program (Biotek, Vermont).
The percentage of hemolysis was calculated from the following formula:
% Hemolysis =.

OD of the specific NaCl concentration

.

OD of 100% hemolysis (0% NaCl)
For each drug treatment, osmotic fragility curves were prepared by plotting % hemolysis
versus % NaCl in GraphPad Prism4 (GraphPad Software Inc.San Diego, CA). Statistical analysis
(non parametric Mann Whitney test) was done in Prism 4.
5.2.5

THP-1 Cell Culture
The acute monocyte-like cells THP-1 were purchased from American Type Culture

Collection (ATCC TIB 202, Rockville MD). The cells were maintained in complete media
composed of RPMI-1640 containing 10 mM Hepes buffer, 1 mM sodium pyruvate, 1 mM Lglutamine, 4.5 g/l D-glucose, 0.05 µM 2-mercaptoethanol and 10% fetal bovine serum. Cells
were kept in tissue culture flasks in a humidified incubator at 370C, 5% CO2.
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5.2.6

THP-1 Membrane Fragility Experiments

Cells were pelleted by centrifugation at 250 x g, 40C, for 10 minutes. The supernatant was
discarded and the pellet was resuspended in 1.0 ml AS. Viability, as checked by trypan blue,
ranged between 95 – 99 %. Cells were enumerated and split into two tubes. In one tube labeled
as Thal-THP-1, thalidomide was added at 4 µg/ml; whereas, in another tube, an equivalent
volume of AS was added and the tube was labeled as A/S-THP-1. The tubes were placed on a
rocker for 30 minutes at room temperature (RT). The cell suspensions were then centrifuged at
250 x g for 10 minutes, 40C. Supernatants were discarded and the pellet of each tube was
resuspended in 1.0 ml AS. Cells were added in each well of plates containing dilutions of salt as
described in Table 1. The plates were incubated at RT for 30 minutes. After centrifugation 230 x
g for 15 minutes at RT, supernatants were harvested and stored at – 800C.
5.2.7

Isolation of Neutrophils and Fragility Experiments
The dextran sedimentation technique, as described in the Current Protocols in

Immunology, was used (Wiley and Sons., 2003). Briefly, whole blood was mixed with an equal
volume of 3% dextran solution. After 20 minutes of incubation at RT the upper layer was
collected in a clean tube. The suspension was pelleted at 250 x g, 50C for 10 minutes. The pellet
was resuspended in normal saline and mononuclear cells were removed by Ficoll-Hypaque
gradient centrifugation. The RBC/neutrophil pellet was subjected to hypotonic lysis to remove
the RBC. After the final wash the neutrophils were resuspended in PBS containing 10 mM Dglucose solution. The cells were pre-treated for 30 minutes with either thalidomide at 4.0 µg/ml
or acid saline control. Cells were then exposed to various salt solutions as mentioned in Table 1.
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After 30 minutes of incubation at RT, plates were centrifuged at 250 x g at RT for 10 minutes;
100 µl of supernatant was transferred from each well in a plate and frozen at –70 0C.
5.2.8

LDH Assay
Supernatants were thawed and dispensed at 50 µl/well in microtiter plates. The Cyto Tox

96 ® non-radioactive cytotoxicity assay (Promega, WI, USA) was used to assess the LDH
presence in the supernatants. The substrate was reconstituted in assay buffer and 50 µl of this
substrate mix was added into wells containing the supernatants. The plate was covered and
incubated in the dark, at RT for 30 minutes. The reaction was stopped with 50 µl /well of stop
solution and absorbance was determined at 490 nm. . The intensity of color produced is directly
proportional to the concentration of LDH in the culture supernatants. The OD obtained was used
to calculate the % LDH from the following formula:
% LDH =. OD of experimental wells. x 100
OD at maximum lysis (i.e. 0% NaCl)
5.3 Results
5.3.1

Thalidomide Stabilized the Erythrocyte Membrane
In blood that was washed and at most of the salt concentrations tested, a significant

reduction in % lysis was observed in thalidomide treated cells compared to AS treated controls.
In blood that was not washed, no significant difference was obtained between drug and AS
treated blood (Figure 5.1).
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Figure 5.1. Osmotic Fragility Experiment of Washed Versus Not Washed RBC. Not washed
blood (A) or washed blood (B) was incubated for 30 minutes with thalidomide or acid saline.
Osmotic fragility experiment was done. The % hemolysis of RBC was plotted against the
different hypotonic NaCl solution Values represent average +/-standard deviation of 5
experiments containing 4 replicate wells per treatment. * p <0.05, **p <0.01 and ***p <0.001
(Mann-Whitney U test).
5.3.2

Effect of Thalidomide on LDH Release by Neutrophils
At 0.05 % NaCl, the median % LDH of thalidomide treated cells was markedly lower

than that of acid saline treated; however, it was not significant (p = 0.1359). At all salt
concentrations, no significant difference in LDH release was obtained between drug and solvent
treated PMN (Figure 5.2).
5.3.3

Effect of Thalidomide on LDH Release by THP-1 cells
Although the median % LDH from thalidomide-treated cells was slightly lower than that

of acid saline treated cells, especially at 0.2 % salt concentration, no significant difference was
obtained between drug and control groups (Figure 5.3).
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Figure 5.2.Lactate Dehydrogenase (LDH) Release Assay of Thalidomide-Treated
Neutrophils (PMN). PMNs, isolated from 3 healthy subjects, were pre incubated with
thalidomide (hatched box) or acid saline (open box) and exposed to different concentrations of
buffered NaCl

Figure 5.3. Lactate Dehydrogenase Release Assay of Thalidomide-Treated THP-1 Cells.
THP-1 monocyte-like cells were incubated with thalidomide (hatched bar) or acid saline (open
bar) and subjected to solutions with different salt concentration. Cytotoxicity was measured by
quantifying the amount of LDH released. .
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5.3.4

Influence of Ingested Thalidomide on Osmotic Fragility of RBC
The ex vivo osmotic fragility experiments showed no significant difference between pre-

thalidomide and post-thalidomide.

The usual pattern with increased lysis at low salt

concentration and gradual decrease in lysis as isotonic normal saline was approached in all
experiments (Figure 5.4).

Figure 5.4. Osmotic Fragility of RBC from Subjects Treated with Thalidomide In Vivo.
Blood was drawn from 12 subjects before (A1) and after (A2) intake of thalidomide. The placebo
group of 4 subjects is illustrated as (B1) and (B2).
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5.4 Discussion
The beneficial effect of thalidomide in the treatment of inflammatory conditions has been
well established. But no definitive mechanism for this anti-inflammatory property has been
obtained so far. A characteristic common to such conditions treated by thalidomide is an influx
of PMNs at the site of inflammation, resulting in tissue damage (Mabalay, M.C. et al, 1964;
Burns, R.A. et al, 1985).
A straightforward hypothesis for thalidomide’s anti-inflammatory mechanism may be a
perturbation of membranes on cells with immune potential. It has been shown that thalidomide
did not alter mononuclear cell surface molecules like CD4, CD5, CD2, CD8, HLA-DR, HLA-A,
B and C (Shannon, E.J. et al, 1994). Inhibition of functions of inflammatory cells like PMN
phagocytosis and/or perturbation of membranes inhibiting the oxidative burst may also be
another possibility. Thalidomide has failed to influence the oxidative burst of neutrophils as
shown in chemiluminescence as well as in NBT reduction assays (Barnhill, R.L. et al, 1984;
Golhman-Yahr, M. et al, 1978). This drug showed a bimodal activity with suppression of
phagocytosis of latex beads by PMNs at a higher concentration and enhancement at a lower
concentration (Barnhill, R.L. et al, 1984). But, it failed to affect the phagocytosis of larger
particles like zymosan (Hastings, R.C. et al, 1978).
The initial step in the oxidative burst event is the reduction of oxygen to O2- at the expense
of NADPH. This reaction is catalyzed by neutrophil membrane-associated enzymes known as
NADPH oxidase. Agents that perturb the integrity of the PMN and/or the lysosome membranes
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have been demonstrated to significantly reduce the production of reactive oxygen species (Wiles,
M.E et al, 1994; Hastings, R.C., 1971). Membrane stabilization of neutrophils as well as other
eukaryotic cells as a possible mechanism of anti-inflammatory role exerted by thalidomide was
investigated.
Certain drugs like the macrolide antibiotics erythromycin and clarithromycin are shown to
exert their anti-inflammatory action by stabilizing PMN membranes (Eriksson, T. et al, 1997).
Thalidomide stabilized the RBC membrane as seen by the reduction in the percentage hemolysis
of RBC exposed to low salt concentrations. This stabilization was confined to washed blood
only. Thalidomide failed to affect the integrity of RBCs from blood that was not washed. This
could be due to binding of thalidomide to proteins like human serum albumin and effectively
depleting the concentration of thalidomide in the plasma (Eriksson, T. et al, Al., 1997).
However, concentrations of thalidomide as high as 16 µg/ml in not washed RBC did not alter the
integrity of the membranes (data not shown). Washing would remove these proteins increasing
the interaction of the drug with RBC membranes.
The ex vivo study of osmotic fragility on blood samples from human subjects before and
after ingestion of 100 mg/ml thalidomide tablets, revealed no significant difference in the
resilience of the RBC to the hypotonic solutions before and after intake of thalidomide. The
concentrations of unhydrolysed thalidomide under this steady state condition are likely to be
between 2 and 4 µg/ml (Eriksson, T. et al, 1997). Partial interaction of thalidomide with soluble
proteins might have hindered the stabilization effect of thalidomide.
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Lactate dehydrogenase, a stable cytosolic enzyme released during cell lysis, was used to
assess the effect of thalidomide on neutrophils and THP-1 cell membranes. There was no
significant difference between thalidomide-treated neutrophils compared to AS treated-ones. The
membrane stabilizing property of macrolide antibiotics is strongly associated with significant
reduction in the oxidative burst by PMN (Theron, A.J. et al, 2000). The lack of stabilizing effect
on PMN by thalidomide in this study is in concordance with previous findings where
thalidomide failed to affect the production of reactive oxygen intermediates by neutrophils
(Barnhill, R.L. et al, 1984; Golhman-Yahr, M. et al, 1978).
To assess the effect of thalidomide on monocyte/macrophage membranes the monocyte
like cell THP-1 was used. Although thalidomide was previously reported to suppress the
production of ROI by activated human monocyte in a chemiluminescence assay (Barnhill, R.L.
et al, 1984), a difference between drug treated and solvent treated THP-1 cells was not seen.
This confirms other studies that the anti-inflammatory mechanism of thalidomide is not
explained by events associated with the modulation of superoxide anions.
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CHAPTER 6 CONCLUSION
The objectives of this work were to study the immunomodulatory, anti-inflammatory and
anti-microbial properties of thalidomide in relation to leprosy. Elucidating the mechanism behind
the dramatic effect of thalidomide in the treatment of ENL would facilitate an understanding of
the cause(s) of ENL and the development of non-teratogenic analogues that can be used in the
treatment of ENL.
The influence of thalidomide on the immune response of leprosy patients’ cells, with ENL
and RR or without reactions, to M. leprae-specific antigens was assessed. In the main phase of
the study lymphocyte proliferation assays and the assessment of the synthesis of TNF-α were
performed. The effect of thalidomide on these two parameters was controversial. Thalidomide
has been previously reported to suppress TNF-α (Sampaio, E.P., et al 1991) or enhance TNF-α
(Shannon, E.J. and Sandoval, F., 1996). In lymphocyte proliferation studies, thalidomide
enhanced (Marriott, J.B. et al, 2002; Corral, L.G. et al, 1999 Haslett, P.A.J. et al, 1999),
suppressed (Keenan, R.J. et al, 1991) or had no effect (Günzler, V. et al, 1986 Santos-Mendoza,
T. et al, 1996; Shannon, E.J. and Sandoval, F., 1995). In some of these studies, the method of
thalidomide preparation was not described or used procedures that indicate probable degradation
of thalidomide. In other studies, concentrations as high as 50 µg/ml were used. In this study,
thalidomide was prepared with an awareness of its susceptibility to hydrolysis and used in
concentrations equivalent (i.e. 4.0 µg/ml) to that achieved in the plasma of patients treated for
ENL.
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In the first phase of the study, with the exception of a significant enhancement of
proliferative responses to DHAR antigen in RR patients, thalidomide failed to modify the ability
of cells to incorporate 3H-Thymidine. Thalidomide suppressed TNF-α in response to DHAR in
healthy controls. Patients with ENL did not respond well in the assays to the AFB, DHAR or
PPD antigen preparations. The majority of these patients were being treated with prednisone and
their cells were probably in a hyporeactive or anergic state. Interestingly, in 4 of 7 RR patients,
thalidomide enhanced the production of TNF-α in response to AFB. Some of these RR patients
were under steroid treatment. This prompted further investigation of this observation among
non-steroid-treated RR patients.
In a second phase of the study, a significant enhancement in proliferation in response to
DHAR and the cytosolic antigen MLSA was observed in non-treated RR patients. In the RR
group as well as the non-reactional leprosy controls and the healthy controls, TNF-α was
significantly suppressed due to thalidomide treatment. This confirmed a recently reported costimulatory property of thalidomide (Marriott, J.B. et al, 2002), which might explain the absence
of effect against RR. As in the first phase of the study, 11 of 68 RR patients responded to
treatment with thalidomide and AFB, with enhanced lymphocyte proliferation, enhanced
expression of TNF-α mRNA and enhanced the synthesis of TNF-α.
In a third phase of this work, the effect of thalidomide on the viability of M. leprae was
assessed. Histopathologic studies of ENL have indicated the abundant presence of granulated M.
leprae in lesions. The mechanism behind the release of M. leprae antigen from macrophage from
certain lepromatous leprosy patients is not understood. Whether thalidomide interferes with the
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viability of intracellular M. leprae and thereby may retard the release of M. leprae antigens was
investigated. Mouse peritoneal macrophages non-activated or IFN-γ-LPS-activated and infected
with M. leprae were treated with thalidomide in culture. This drug failed to affect the viability of
intracellular M. leprae in a significant manner in the non-activated or activated macrophages.
Thalidomide did not influence the production of neither TNF-α nor NO2- by these activated and
infected macrophages.
Thalidomide had been shown to stabilize lysosomal membranes derived from rat liver
homogenates. This property of thalidomide was proposed as its possible anti-inflammatory
mechanism in the treatment of ENL (Hastings, R.C. 1971). In the last phase of this study the
effect of thalidomide on the plasma membranes of neutrophils, THP-1 cells and red blood cells
was studied. Thalidomide failed to protect the plasma membrane of neutrophils and THP-1 cells
from osmotic lysis. In vitro, thalidomide stabilized RBC in blood depleted of plasma but it failed
to do so in whole blood and in the blood of normal males ingesting thalidomide.

Overall

thalidomide did not alter the viability of M. leprae, nor the integrity of the plasma membrane of
inflammatory cells. It could enhance or suppress M. leprae antigen-induced synthesis of TNF-α.
Interestingly, in 15 of 75 RR patients cells stimulated with AFB, thalidomide acted as a costimulant enhancing cell proliferation, synthesis of mRNA for TNF-α and TNF-α.
Thalidomide’s enhancing effect on TNF-α in RR appears to be dependent on the stimulant and
IL-2 signaling. As the inflammation in RR is associated with the emergence of antigen-reactive
T-cells and TNF-α, we speculate that the use of thalidomide in the treatment of RR may
exacerbate the reaction.
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APPENDIX - RELEVANT EXTRA MATERIAL
DEVELOPMENT AND VALIDATION OF A GEAOGRAPHIC INFORMATION RISK
ASSESSEMENT MODEL FOR THE CONTROL OF LEPROSY IN ETHIOPIA
Introduction
The multi-drug treatment approach of the WHO Global Leprosy Elimination Campaign
has reduced the prevalence of leprosy in the world. According to WHO, since 1985, the global
prevalence has been reduced by 90 % with a current prevalence/10,000 of 1.4 (Int. J. Lepr. Other
Mycobact. Dis S21-S22, 2002). However, this reduction in prevalence does not appear to be
successful in interrupting the transmission of leprosy. For the past 10-15 years, stable numbers of
new cases have been recorded yearly, and in the 6 countries that account for approximately 90 %
of new cases the incidence is even rising (Durheim, D.N. and Speare, R., 2003; Lockwood
D.N.J., 2002). This increase in incidence is explained by some agencies to be due to increased
detection of hidden cases through improved case detection services and special education
campaigns. Although this might be true for the incidence among patients with advanced disease
or disability, it does not explain why children make up 13 % of the new cases (Lockwood, D.N.J.
2002).
The relationship among Mycobacterium leprae, the human host and the chain of
infection, which may lead to development of leprosy, are not clear. Leprosy is believed to be
transmitted by inhalation of nasal droplets containing M. leprae. Lepromatous leprosy (LL)
patients, who harbor viable bacilli in nasal secretions, are thought to be the main source of
infection (Hastings, R.C., 1993). Yet little correlation exists between prevalence of LL and the
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total new cases registered. The incidences of conjugal leprosy and of individuals with frequent
contact with cases are also insignificant (Jopling, W.H., 1988).
The rate of infection by M. leprae is much greater than the rate of disease development
indicating the presence of sources of infection other than the leprosy patients (Fine, P.E. et al,
1997). Alternative sources of M. leprae infection could be a sub-clinically infected individual, an
animal or insect vector or a contamination in the environment.
According to the WHO, Ethiopia in 1999 reached the leprosy elimination target of 1case
/10,000 populations; however, as with other countries, the incidence has not changed appreciably
with about 5,000 new cases detected yearly. In 2002, clusters of endemicity with prevalence
rates higher than the elimination target was recorded in 4 of the 14 administrative divisions
namely the Oromia, Amhara, the Southern Nations and Nationalities (SNNP) and Tigray
(Tuberculosis and Leprosy Control of Ethiopia10th Annual Review Meeting, 2002).
Environmental sources have long been suspected to play a role in the spread of leprosy
especially due to the geographical differences in leprosy distribution and local clustering.
Previous beliefs that M. leprae cannot survive once outside the human body are now changing.
Under favorable conditions such as hot humid climate, M. leprae is capable of surviving for
months (Dessikan, K.V. and Sreevatsa, 1995).
An objective of this work was to use geographic information systems (GIS) to assess the
influence of environmental factors on the prevalence of leprosy in Ethiopia. The application of
GIS in epidemiology has facilitated our understanding of spatial variations of diseases and their
relationship to the environment. The environmental attributes selected for analysis were
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normalized difference in vegetation index (NDVI), earth surface temperature (TMax), and a
climate data including point potential evapo-transpiration (PPE), average maximum and
minimum temperatures. These attributes were analyzed for their suitability for leprosy
prevalence in the Oromia region in Ethiopia. Arc View GIS 3.3 and Genetic Algorithm for Ruleset Prediction (GARP) were used to build models and to create maps showing the distribution of
leprosy in the region. The independent leprosy data set from the Amhara region was then used to
validate the leprosy prediction model.
Material and Methods
Baseline Data. The data was prepared by the Amhara and Oromia Regional Bureaus of Health
and the Ethiopian Ministry of Health. Cases include both the severe forms of multibacillary
leprosy (MB) as well as the milder form known as paucibacillary leprosy (PB). As of June 2001,
the total number of PB (N=1367) and PB (318) cases recorded in 285 zonal health institutions in
the Amhara region was used in this study. The total PB (N=136) and MB (N=2402) cases for the
Oromia region collected as of August 2003, comprised data from 124 health institutions.
Determination of geographical coordinates. The latitude and longitude of each clinic was
obtained in geographic decimal degree format from the website of the National Imagery and
Mapping Agency NIMA)(http://gnps.www. nima). Coordinates not found were obtained from
Encarta (Microsoft Encarta, 2002). Digital mapping of the point coordinates for each clinic was
prepared in Arc View GIS 3.3.
The Minimum Medical Database (MMDb). This database was prepared by collaborating health
workers and earth scientists interested in the application of geospatial sciences to control
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program management and research for schistosomiasis and other snail-borne diseases. The
database contains information for the Intergovernmental Authority of Development/Nile Basin
(IGAD/Nile) region of East Africa, which includes Ethiopia. The MMDb available in CDROM
(http://www.gnosis.org) contains useful maps and compiled data on environmental attributes
such as normalized difference in vegetation index (NDVI), earth surface maximum temperature
(TMax), elevation, soil types; infrastructures like roads, rail roads, utility lines; political
boundaries and population data for the region of East Africa (Malone, J.B. et al, 2001). All
parameters tested in this study were taken from the MMDb .
Table.1. Data Used for Analysis
Parameter
NDVI
TMax
ACT Climate
NDVI,
GARP

TMax

Feature Type Source
8-bit Image
United States Geological Survey (USGS)
16-bit Image
USGS
Grid
Blackland Research and Extension Center, Texas
Agricultural experiment station
for Image
Clipped and modified with GARP Dataset Manager

Prevalence Calculation and Normalization of Data. To avoid confounding factors like clinic size
and number of people living around each clinic and to obtain comparable data, we calculated the
prevalence of leprosy per 10,000 populations for both the Amhara and Oromia regions.
Oromia Region: the data for this region contains number of inhabitants in each zone. We
used these data to calculate the prevalence of leprosy/10,000 for each clinic.
Amhara Region: the total population per each zone was estimated by creating a 10-km
diameter buffer zone surrounding each leprosy clinic and extracting the density; the total
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population was calculated from the population density and used for the determination of
prevalence/10,000 for each clinic.
Extraction of Environmental Data. All extractions of environmental feature data, including
Advanced Very High Resolution Radiometer (AVHRR) satellite sensor data, were based on the
10-km diameter buffer zone around each clinic. We used the Oromia data for creation of models
and the Amhara data for validation of created models.
Normalized Difference in Vegetation Index NDVI (1992-1995)
AVHRR data for daytime land surface temperature (TMax) and Normalized Difference
Vegetation Index (NDVI) for 1992-1993 and 1995-1996 was obtained from the United States
Geological Survey (USGS) global 1km2 website (Huh, O.K. et al, 2001). NDVI is an index that
ranges from 0 to 200 with increasing green vegetation. It is an indicator of soil moisture based on
vegetation. The AVHRR data, which consists of decadal (10-day) composites of daytime
imagery, was processed by the USGS to minimize cloud cover and atmospheric attenuation of
sensor signal. All downloaded images were calibrated and geo-referenced to a geographic
decimal degree latitude and longitude coordinate system using ERDAS imagine 8.6 image
processing software. The decadal images were averaged to create monthly composites, which
were averaged together to create maps for dry (October-March) and wet (April-September)
seasons and an annual composite map, which included both seasons.
The NDVI image files were converted into a grid file and used for extraction of mean
NDVI value for each buffer zone. The extracted data were exported as Dbase files into Microsoft
excel datasheets. Scatter diagrams of Cases/10,000 versus mean NDVI were plotted in Microsoft
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Excel. Outliers such as buffer zones falling fully or partially in water were excluded. A range of
NDVI that comprises all prevalence data points was determined from the plot and used to
perform queries in Arc View 3.3 GIS to create map overlays showing areas suitable for leprosy
prevalence.
TMax, (1992-1995)
TMax is the earth surface maximum temperature from AVHRR channel 4, which is used
as an indicator of temperature (Huh, O.K. et al, 2001). Similar to the NDVI data, the image files
for TMax were prepared for the dry, wet and annual seasons. The same extraction procedures
were applied to obtain a range of TMax suitable for the prevalence of leprosy in the regions.
Scatter plots were prepared in Microsoft excel and the range was then used as the criteria for
queries in Arc view 3.3 GIS to create map overlays. The Amhara prevalence data points were
overlaid on the model and points falling inside and outside the model were determined for
calculation of positive and negative predictive values.
Almanac Characterization Tool (ACT) Climate Data. This is a climate grid file (5 x 5 km2 cell
size), which contains 30 years average data for precipitation (pre), potential evapo-transpiration
(pet), point potential evapo-transpiration (ppe= pre/pet) and the minimum (It) and maximum
temperature (xt) for January up to December. Ppe is an indicator of water budget of the soil. The
leprosy prevalence point table was joined to the climate data table based on the grid cell. The
linked tables was exported as a DBase file and mean temperature ([It +xt]/2) and mean ppe were
calculated for dry season (October to March) and wet season (April to September) to give dry T,
wet T, dry PPE and wet PPE values. Scatter plots of these values versus the stratified
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prevalence/10,000 (0-0.1, 0.1-0.7 and > 0.7) were used to define ranges that included 95% of all
points (Table 2) for creation of map overlays in Arc view 3.3 GIS.
Ecologic Niche Modeling GARP. The annual composites data for TMax and NDVI were used as
environmental dimensions for the ecologic niche modeling. Environmental layers for the analysis
were prepared by converting the image files to grid and processing of these files using the GARP
module in Arc View GIS 3.3. These files were transformed to GARP compatible format with the
GARP Dataset Manager. The Amhara and Oromia leprosy prevalence data were combined to
generate a total of 317 occurrence points. These distributional points were loaded into Desktop
GARP and used to model ecologic niches and potential geographic distribution of M. leprae.
GARP equally divides the loaded prevalence data into training and test data sets. Multiple
iterations based on rule selection, evaluation, testing and incorporation or rejection is performed.
The training data sets are subjected to randomly selected statistical methods like logistic
regression, bioclimatic rules to develop a procedure to be used to evaluate the predictive
accuracy based on test data sets and points randomly sampled from the whole region as a whole
(Towsend, A.P. et al, 2001). For each set of data used GARP generates 20 models. Three criteria
were used for the selection of the best model; (1) elimination of models with high number of
training points omitted and when possible including only those models with 0 omission; (2) the
average of total area predicted for species to be present was calculated and models falling within
5% range below or above this average were selected and (3) models that passed the two criteria
were compared based on the p value for Chi-square analysis of the probability of a random
sample predictions being similar to the one generated by GARP.
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Results
Point locations of the 123 health institutions in the Oromia region and the 285 health institutions
in the Amhara region were mapped in Arc View 3.3.
Scatter plots of Oromia prevalence data versus NDVI or TMax, prepared in Microsoft Excel,
were determined to define ranges that included 95 % of all leprosy prevalence points. The NDVI
value ranges were 116-154.5 for the annual composite, 116-161 for the dry season map and 115155 for the wet season map. TMax ranges were 9.4-28.80C for the annual composite, 11.732.50C for the dry season map, 7.7-25.80C for the wet season map. These ranges were used to
prepare query-based map overlays showing all areas that met both the NDVI and TMax criteria
ranges in the country. We selected the annual composite model that covers all seasons
throughout the year. This model showed except for areas in the South East (Somali) and North
East (Afar), that most places in the country were found to be suitable for leprosy (Figure 1). The
positive predictive value calculated using the Amhara data was 90.5 %. All of the prevalence
points that fell outside the predicted area were in the lowest ranges of prevalence/10,000 (0 –
0.1).
The ACT climate grid was used to determine the influence of thermal-hydrologic regime (PPE
and PET) in relation to leprosy distribution. Table.2 shows the defined ranges of potential evapotranspiration and minimum and maximum temperatures for the dry and wet seasons The climate
model predicted most of the Amhara and the Oromia region except the southern part, most of the
Southern Nation and Nationality (SNNP), Harari and DireDawa (Figure 2.). The model excluded
Somali, most parts of Afar especially the Eastern part, Northern Tigray and Western Gambela.
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The positive predictive value generated using the Amhara data was 87.8%. Except for Chagnie
(prevalence/10,000 = 1.32), all the prevalence points not predicted by the model had a
prevalences/10,000 in the 0-0.1 ranges.

.
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Table 2. Temperature and PPE Ranges Used in ACT Climate Query
Prevalence
Class
0 - 0.1
0.1 - 0.7
> 0.7

Dry season T in Wet season T in Dry
season
0
0
C
C
PPE
11.6 - 17.9
11.6 - 21.0
0.12 - 0.42
9.8 - 24.3
9.6 - 25.3
0.12 - 0.6
8.9 - 21.8
9.7 - 24.5
0.13 - 0.76
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Wet season PPE
1.03 - 2.61
0.59 - 2.9
0.6 - 3.05

The GARP M. leprae distribution model is the most powerful of all models due to
restrictions and statistical methods employed for its generation. This model is inclusive of all of
the Amhara and Oromia points while the other two models were based on the Oromia data only.
The prediction pattern of this ecologic niche model resembles the annual composite prediction
model. It included most of the Amhara, Oromia, SNNP, Tigray and Gambela regions and
excluded the Afar and Somali regions (Figure.3).
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Discussion
Understanding of the natural history of a disease, its ecologic distribution and the
essential host-pathogen interactions are necessary in order to establish a successful control
program. The WHO leprosy elimination campaign, mainly based on case finding, treatment and
follow-up of household contacts, has not reduced the incidence of leprosy. Enhanced detection of
hidden cases cannot explain the new occurrence of leprosy among young children, an indicator
of ongoing active transmission (Int. J. Lepr. Other Mycobact. Dis S21-S22, 2002).
Several countries that reached the elimination target have localities with clusters of
leprosy. These high endemicity regions must be eliminated in order to achieve sustained low
transmissions and reduced incidence rates. Ethiopia is one example where leprosy elimination is
achieved but there are districts with leprosy prevalence above the 1 case/10,000 cut-off defined
by WHO to be an endemic area. The transmission rate in children below 15 years of age is about
6%. Out of the total leprosy cases recorded in Ethiopia in 2002, 46% occurred in Oromia, the
largest administrative region in the country, followed by the Amhara region with 31.5 % of the
total new cases (Tuberculosis and Leprosy Control of Ethiopia10th Annual Review Meeting,
2002).
GIS techniques were used in the current study to develop leprosy prediction models for
Ethiopia. Thermal-hydrologic regime, as defined by AVHRR satellite sensor data on moisture or
humidity, land surface temperature plus conventional climate data were included as potential
environmental factors that might determine the distribution and abundance of the disease.
Annual composite image files for NDVI, an indicator of moisture regime and vegetation vigor,
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and TMax an indicator of temperature regime (Huh, O.K. and Malone, J.B., 2001) were used to
create the AVHRR satellite sensor based model. This TMax/NDVI combined model showed a
major part of the country was suitable for occurrence of leprosy. A second model based on
climate station data on precipitation (PRE), Potential evapo-transpiration (PET), the PRE/PET
ratio also known as point potential evapo-transpiration (PPE) and maximal and minimal
temperatures for each month was also created. PPE indicates the moisture content of soil (water
balance) was included to validate the previously reported association of M. leprae with moisture
(10). The climate-based model with stratified prevalences (0-0.07, 0.07 – 0.1 and 0.1 to 71.3
cases/10,000 population) predicted the highest risk in Amhara and Oromia, the two regions with
highest leprosy incidence (Tuberculosis and Leprosy Control of Ethiopia10th Annual Review
Meeting, 2002).
The ecologic niche of a species is the suitable ecologic space within which a species is
potentially able to maintain population without immigration. GARP is a high precision computer
based genetic algorithm system used in ecologic niche modeling. It has a high predictive ability
of species potential distributions based on user selected environmental layers. GARP
incorporates different procedures that involve powerful rules including atomic rules, logistic
regression analysis and the frequency distribution-based bioclimatic rules. The GARP model has
minimum errors of omissions and commissions making it an important tool in understanding the
geographical distribution of the species of interest (Townsend, A.P. et al, 2001; Costa, J. et al,
2002).
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The third model GARP, based on input variable of NDVI and TMax annual composite
value confirmed what we saw in the annual TMax/NDVI model. It predicted most of Amhara
and Oromia regions as the two major leprosy areas in Ethiopia.
All three models excluded the dry and hot Afar and Somali area, the 2 regions with the
least number of leprosy cases in Ethiopia in 2002 (Tuberculosis and Leprosy Control of
Ethiopia10th Annual Review Meeting, 2002).
M. leprae is capable of withstanding severe adverse environmental conditions while to
remain viable. Hot and humid weather, wet soils, water and low temperatures, are all
demonstrated to favor survival of the bacilli for a few months (Desikan, K.V. and Sreevatsa,
1995; Desikan, K.V., 1977). M. leprae DNA has been detected in water in Indonesia at locations
where a high proportion of individuals utilizing this water were affected by leprosy (Matsuoka,
M. et al, 1999). A well-controlled study in Karonga district in Malawi has shown water and soil
moisture to be associated with high prevalence of leprosy (Sterne, J.A.C. et al, 1995). Indirect
transmission of leprosy is further supported by the natural occurrence of leprosy in animals like
armadillos (Job, C.K. et al, 1986) and reports on the potential of insects to transmit leprosy
(Geater, J.G., 1975; Banerjee, R. et al, 1990).
Our study indicates that leprosy may be associated with specific environmental features.
The models we developed seem to be in concordance with leprosy distribution in Ethiopia and
support the conclusion that: (1) certain thermal-hydrological regimes favor survival of leprosy in
the environment and that (2) both NDVI and TMax may be incorporated in the predictive model
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of leprosy. This can be measured by conventional climate station data or by satellite-sensor data
on NDVI and TMax as surrogates of moisture and temperature respectively.
Various parameters have been identified as risk factors in acquiring leprosy disease.
These include demographics like age and sex and immunological factors like the absence of
BCG vaccination (Ponnighaus, J.M. et al, 1993). A significant negative correlation between the
incidence of leprosy and higher economic indices has been reported (Di, Z. et al, 1993). Rural
endemic settings with poor housing and sanitation conditions have been described as important
factors in the transmission of leprosy (Mani, M.Z., 1996). For any of these factors to have a role
in the development of leprosy, the sustained presence of M. leprae in the environment is
necessary. We propose that leprosy occurs most frequently when a suitable microenvironment
like moist soil coexists with other known or unknown predisposing factors. This study provides
evidence that environmental factors are of importance in the prevalence of leprosy. Such factors
must be taken into consideration when planning a control program. Further studies that
incorporate field-collected validation data (ground truth) may shed more light into the precise
thermal-hydrological regime factors or other risk factors associated with the environmental risk
of leprosy.

108

Reference
Banerjee, R., Chaudhury, S. and Hati, A.K. 1990. Transmission of Mycobacterium leprae from
lepromatous leprosy patients to the skin of mice through intermittent feeding.Trop. Geog.
Med. 42(1): 97-99.
Costa, J., Towsend, A.P., Beard, C.B. 2002. Ecologic niche modeling and differentiation of
populations of triatoma brasiliensis neiva, 1911, the most important Chagas’ disease vector in
Northeastern Brazil. Am. J. Trop. Med. Hyg. 67(5): 516-520.
Desikan, K.V., Sreevatsa. 1995. Extended studies on the viability of M. leprae outside the human
body. Lep. Rev. 66: 287-295.
Desikan, K.V.1977. Viability of Mycobacterium leprae outside the human body. Lep. Rev. 48:
231-235.
Di, Z., Yuewen, N. and Jingzeng, Z. 1992. Leprosy-economy-environment; might we predict
leprosy incidence from this point of view? Int. J. Lep 61(4): 631-632.
Durrheim, D.N., Speare, R. 2003. Global leprosy elimination: time to change more than the
elimination target. J. Epidemiol. Comm. Health 57: 316-317.
Fine, P.E., Sterne, J.A., Ponnighaus, J.M., Bliss, L., Saui, J., Chihana, A., Munthali, M.,
Warndorff, D.K. 1997. Household and dwelling contact as risk factors for leprosy in Northern
Malawi. A. J. Epidemiol. 146(1): 91-102.
Geater, J.G. 1975. The fly as potential vector in the transmission of leprosy. Lep. Rev. 46: 279286.
Hastings RC. 1993. Leprosy. 2nd edition, RC Hastings, Ed; pp 137-155. Churchill Livingston,
Edinburgh, UK.
Huh, O.K. and Malone, J.B. 2001. New tools: potential medical applications of data from new
and old environmental satellites. Acta Tropica 79(1): 35-47.
Job, C.K., Harris, E.B., Allen, J.L. and Hastings, R.C. 1986. A random survey of leprosy in wild
nine-banded armadillos in Louisiana. Int. J. Lep. 54(3): 453-457.
Jopling, W.H. 1988. Handbook of leprosy. 4th edition. Heinemann Professional Publishing
109

Lockwood, D.N.J. 2002. Leprosy elimination- a virtual phenomenon or a reality. B.M.J. 324:
1516-1518.
Malone, J.B., McCarroll, J.C., Kristensen, T.K., Yilma, J.M., Erko, B., El-Bahy, M.M. and
Corbett. 2001. Minimum Medical Database spatial decision support system for the Authority
on development-Nile Basin Region (IGAD-Nile).
Mani MZ. 1996. Ecologic factors in transmission of leprosy. Ind. J. Lep. 68(4): 375-376.
Matsuoka, M., Izumi, S., Budiawan, T., Natak, N. and Saeki, K. 1999. M. leprae DNA in daily
using water as a possible source of leprosy infection. Indian J. Lep. 71(1): 61-67.
Ponnighaus, J.M., Fine, P.E., Sterne, J.A., Bliss, L., Wilson, J.R., Malema, S.S. and Kileta, S.
1993. Incidence rates of leprosy in Karonga district, Northern Malawi: patterns by age, sex,
BCG status and classification. Int. J. Lep. 62(1): 10-23.
Sterne, J.A.C., Ponnighaus, J.M., Fine, P.E.M. and Malema, S.S. 1995. Geographic determinants
of leprosy in Karonga district, Northern Malawi. Int. J. Epidemiol. 24(6): 1211-1222.
The Global situation of leprosy control at the beginning of the 21st century. 2002. Int.J.Lep.
70(1S): S21-S22.
Towsend, A.P. and Vieglais, A.D. 2001. Predicting species invasions using ecological niche
modeling: new approaches from bioinformatics attack a pressing problem. Bioscience 51(5):
363-371.
Tuberculosis and Leprosy control of Ethiopia. 2002. Tenth Annual Review Meeting.18 to 20
September, 2002.
WHO leprosy elimination project.
http://www.int/lep/Reports)

Status

110

reports

2003.

WHO

Geneva,

2004

(

VITA
Azeb Tadesse Argaw was born in Addis Ababa, Ethiopia, to Tadesse Argaw Negash and
Asrat Negash H/Wolde. She attended the French school Lycee Guebre Mariam in Addis Ababa.
In December 1991, she completed her Bachelor of Science degree in pharmacy from the Addis
Ababa University. She worked as a research assistant at the Armauer Hansen Research Institute
in Addis Ababa. In August 1995, she went to Bergen, Norway, to pursue her master at the Center
for International Health. In June 1998, she obtained her Master of Philosophy in immunology.
She returned back to AHRI and worked as a senior research assistant. In May 2001, she joined
Louisiana State University as a doctoral student.
She is planning to pursue a postdoctoral work in molecular immunology of multiple sclerosis
at Mount Sinai School of Medicine in New York.

111

